

## CURRICULUM VITAE

### PETER ROBERT MARTIN

**ADDRESS:**

Department of Psychiatry and Behavioral Sciences  
Vanderbilt Psychiatric Hospital  
Suite 3035, 1601 23<sup>rd</sup> Avenue South  
Nashville, Tennessee 37232-8650  
U.S.A.

Phone: 615-343-4527

Mobile: 615-364-7175

E-Mail: [peter.martin@vumc.org](mailto:peter.martin@vumc.org)

[peter.martin@vanderbilt.edu](mailto:peter.martin@vanderbilt.edu)

<https://orcid.org/0000-0003-2292-4741>

**WEBSITES:** <https://wag.app.vanderbilt.edu/PublicPage/Faculty/Details/27348>  
<http://www.vanderbilt.edu/ics/>

**DATE AND PLACE OF BIRTH:** September 6, 1949, Budapest, Hungary

**FAMILY:** Married Barbara Ruth Bradford, December 23, 1985

Alexander Bradford Martin, born October 21, 1989

**EDUCATION:**

1967 - 1971	Honours B.Sc. (Molecular Genetics) McGill University, Montreal, Quebec, Canada
1971 - 1975	M.D., C.M. McGill University, Montreal, Quebec, Canada
1975 - 1976	Resident in Internal Medicine, Sunnybrook Medical Centre, University of Toronto, Toronto, Ontario, Canada
1976 - 1978	Research Fellow in Clinical Pharmacology, Clinical Pharmacology Program, Addiction Research Foundation Clinical Institute - Toronto Western Hospital, University of Toronto
1976 - 1979	M.Sc. (Pharmacology) University of Toronto Dissertation: Intravenous phenobarbital treatment of barbiturate and other hypnotic withdrawal: A pharmacokinetic approach.
1978 - 1979	Resident in Psychiatry, Affective Disorders Unit, Clarke Institute of Psychiatry, University of Toronto
1979	Resident in Psychiatry, Hospital for Sick Children, University of Toronto
1980	Resident in Psychiatry, Toronto General Hospital, University of Toronto

**LICENSURE AND CERTIFICATION:**

The College of Physicians and Surgeons of Ontario (License No. 28907), 1976.

The Board of Medical Examiners of the State of Maryland (License No. D26685), 1981.

The Board of Medical Examiners of the State of Tennessee (License No. MD17128), 1986.

Fellow of the Royal College of Physicians (Canada), Psychiatry, 1981.

Diplomate of the American Board of Psychiatry and Neurology, Psychiatry, 1983; Certification in the Subspecialty of Addiction Psychiatry, 1993; Recertification: 2002, 2012 and 2022

**ACADEMIC APPOINTMENTS:**

- 1980 - 1983 Visiting Scientist, Section on Experimental Therapeutics, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland
- 1980 - 1986 Visiting Scientist, Laboratory of Clinical Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
- 1983 - 1986 Chief, Section of Clinical Science, Laboratory of Clinical Studies, National Institute on Alcohol Abuse and Alcoholism
- 1986 - 1992 Associate Professor with Tenure, Departments of Psychiatry and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee
- 1986 - 2013 Founding Director, Division of Addiction Psychiatry (formerly Division of Alcohol and Substance Abuse and then Division of Addiction Medicine), Department of Psychiatry, Vanderbilt University School of Medicine
- 1990 - Faculty, Developmental Psychopathology Research Training Program
- 1992 - Professor with Tenure, Department of Psychiatry and Behavioral Sciences, Vanderbilt University School of Medicine**
- 1992- Professor of Pharmacology**
- 1993 - Investigator, John F. Kennedy Center for Research on Human Development, Peabody College, Vanderbilt University
- 1994 - 2016 Founding Director, Vanderbilt Addiction Center
- 1995 - Investigator, Clinical Nutrition Research Unit
- 1999 - 2015 Director, Vanderbilt Institute for Coffee Studies
- 2015 - Founder and Scientific Director, Institute for Coffee Studies (Edward F. Fischer, PhD, Director)
- 2002 - Scientist, Vanderbilt Brain Institute
- 2002 - Member, Vanderbilt Institute of Chemical Biology
- 2002 - Investigator, Center for Integrative and Cognitive Neuroscience
- 2011 - Member, Vanderbilt Institute for Global Health
- 2016 - Member, Vanderbilt Center for Addiction Research

**HOSPITAL APPOINTMENTS:**

- 1980 - 1983 Clinical Associate, Clinical Center, National Institutes of Health, Bethesda, Maryland
- 1981 - 1986 Consultant Psychiatrist, United States Soldiers' and Airmen's Home, Washington, DC
- 1983 - 1986 Attending Physician, Clinical Center, National Institutes of Health
- 1983 - 1986 Staff Psychiatrist, Counseling and Treatment Associates, Silver Spring, Maryland
- 1986 - 1987 Medical Director, Alcoholism Treatment Program, Nashville Veterans Administration Hospital
- 1986 - 1994 Chief Psychiatrist and Associate Medical Director, Vanderbilt Institute for Treatment of Addiction (VITA), Vanderbilt University Medical Center
- 1995 - 2016 Chief Psychiatrist, Vanderbilt Addiction Center (formerly VITA)

**PROFESSIONAL ORGANIZATIONS:**

- Alcohol and Drug Council of Middle Tennessee, Member (1998 - present)  
American Academy of Addiction Psychiatry, Member (1988 - present), Distinguished Fellow (2010 – present)  
Member, Annual Meeting Program Committee (1999 - present); Co-Chair (2005 – 2007); Chair (2008 – 2010)  
Member, Board of Directors (2005 – 2010; 2011 – 2013)  
Head, Research Section (2011 – 2013)  
American Association for the Advancement of Science, Member (1980 - present)  
American Psychiatric Association, Member (1981 - 1992), Fellow (1992 - 2002), Distinguished Fellow (2003 – 2011), Distinguished Life Fellow (2011 – present)  
Chairman, Alcohol and Drug Committee, Tennessee Psychiatric Association (1989 - 1992)  
President, Middle Tennessee Chapter, Tennessee Psychiatric Association (1993 - 1994)  
Chairman, Membership Committee, Tennessee Psychiatric Association (1994 - 1997)  
Member, Committee on Training and Education in Addiction Psychiatry, Council on Addiction Psychiatry (1999 - 2002)  
American Society of Clinical Pharmacology and Therapeutics, Member (1983 - present)  
Vice-Chairman, Section on Neuropsychopharmacologic Agents (1989 - 1992)  
Chairman, Section on Neuropsychopharmacologic Agents (1992 - 1995)  
Vice-Chairman, Substance Abuse Committee (1995 - 1998)  
Member, Program Committee (1995 - 1996)  
Chairman, Substance Abuse Committee (1998 - 2001)  
Member, Board of Directors (1998 - 2001)  
Association for Medical Education and Research in Substance Abuse, Member (1986 - 1996)  
International Collegium of Composite Diagnostic Evaluation in Psychiatry, Founding Member (1989 - 1992)  
International Society for Biomedical Research on Alcoholism, Member (1991 - present)  
Mental Health Association of Middle Tennessee  
Member, Board of Directors (2003 – 2009)  
Member, Steering Committee, Jack C. Massey Leadership Award (2001, 2003, and 2005)  
Chair, Subcommittee on Message of the Organization (2007 – 2008)  
Member, Advisory Board (2009 – present)  
Research Society on Alcoholism, Member (1987 - present)  
Member, Program Committee, Annual Meeting (1992 and 1993)  
The American College of Psychiatrists, Member (1990 - 2003)  
The Mental Health Association of Tennessee  
Member, Board of Directors (1999 - 2003)

**PROFESSIONAL ACTIVITIES:**

**Clinical Center, National Institutes of Health**

- 1983 - 1984 Member, Working Party to Recommend Guidelines for the Intramural Programs of the National Institutes of Health on the Consent Process with Impaired Human Research Subjects
- 1983 - 1986 Chairman, Clinical Research Subpanel, National Institute on Alcohol Abuse and Alcoholism
- 1983 - 1986 Member, Human Research Review Panel
- 1984 - 1986 Member, Pharmacy and Therapeutics Subcommittee
- 1985 - 1986 Member, Quality Assurance Committee

**Vanderbilt University Medical Center**

- 1988 - 1990 Member, General Clinical Research Center Advisory Committee
- 1988 - 1991 Member, Institutional Review Board for the Protection of Human Subjects: Committee for the Behavioral Sciences
- 1990 - 1991 Chairman, General Clinical Research Center Advisory Committee
- 1990 - 1991 Member, Self-Study Task Force in preparation for Liaison Committee on Medical Education Accreditation Survey, Subcommittee on Graduate Medical Education
- 1991 - 1992 Member, Standing Policy Committee: Biomedical Sciences
- 1992 - 1993 Chairman, Standing Policy Committee, Biomedical Sciences
- 1992 - 1993 Member, Advisory Council
- 1992 - Member, Appointment and Promotions Committee (previously, Tenure and Promotions Committee), Department of Psychiatry and Behavioral Sciences
- 1994 - 1995 Member, Committee on the Use of Cognitively Impaired Persons as Research Subjects
- 1995 - 2001 Member, Medical Board, Psychiatric Hospital at Vanderbilt
- 1995 - 1999 Member, Credentials Committee, Psychiatric Hospital at Vanderbilt
- 1995 - 2001 Member, Medical Student Educational Committee, Department of Psychiatry
- 1996 Participant, Strategic Planning for the Academic Enterprise (Clinical Research Task Force; Basic Research in Clinical Departments Task Force)
- 1996 Participant, Vanderbilt Behavioral Health Care Retreat
- 1996 Member, Planning Committee for 1997 Brain Awareness Week in Nashville
- 1998 Participant, Curriculum Retreat, Vanderbilt University School of Medicine
- 1998 - 1999 Member, Self-Study Task Force in preparation for Liaison Committee on Medical Education Accreditation Survey, Subcommittee on Medical School Departments (Clinical Departments)
- 1998 - 1999 Member, Physician Wellness Committee (an ad hoc committee of the VUMC Medical Board); Chairman, Intervention and Treatment Subcommittee
- 1998 Member, Grant Review Committee (Clinical Science), VUMC Intramural Discovery Grant Program
- 1999 - 2006 Chair, Pharmacy and Therapeutics Committee, Vanderbilt Psychiatric Hospital
- 1999 - Member, Physician Wellness Committee, VUMC Medical Board
- 1999 - 2000 Member, Committee for Preparation of Research Strategic Plan, Department of Psychiatry
- 1999 - 2002 Member, fMRI Infrastructure Grant Committee

- 2000 - 2003 Member, Standing Policy Committee: Faculty
- 2000 - 2006 Member, Clinical Services Governance Council, Department of Psychiatry
- 2002 - 2006 Chair, Advisory Board, the Vanderbilt Comprehensive Assessment Program for Professionals (A. J. Reid Finlayson, M.D., Director)
- 2006 - 2006 Member, VUMC Quality Council
- 2007 - 2008 Member, Basic Science Planning Committees – Enhancing the Reputation of Vanderbilt Research
- 2013 - 2016 Member, My Health at Vanderbilt (MHAV) Safety, Adoption & Effectiveness Workgroup
- 2014 – 2017 Elected Member, Faculty Senate, Vanderbilt University
- 2017 – 2020 Elected Member, Faculty Senate, Vanderbilt University

### **Extramural Activities**

- 1988 - 1994 Advisor, Substance Use Workgroup for the Diagnostic and Statistical Manual, Fourth Edition (DSM-IV), American Psychiatric Association
- 1988 Member, NINCDS Special Review Committee
- 1989 Visiting Professor, Department of Psychiatry, The University of Tennessee, Memphis, Tennessee, March 30-31
- 1989 Visiting Professor, National Institute for Nervous and Mental Diseases, Budapest, Hungary, June 18 - July 12
- 1990 Participant, Gordon Conference on Alcoholism, Oxnard, California, February 5-9
- 1990 - 1995 Member, Scientific Advisory Committee, Alcoholism and Drug Research Communications Center
- 1991 Visiting Professor, Department of Psychiatry and Behavioral Sciences, The University of Oklahoma, Oklahoma City, Oklahoma, April 24-26
- 1994 Member, NIAAA Special Review Committee
- 1994 Member, NIH/NIAAA Special Emphasis Panel ZRG-4 (ALT-3)
- 1998 Faculty, Research Colloquium for Junior Investigators, Annual Meeting, American Psychiatric Association, Toronto, Ontario, Canada, May 31
- 2000 - Examiner in Psychiatry, American Board of Psychiatry and Neurology, Inc.
- 1999 - 2005 Member, Committee on Subspecialty Certification and Recertification in Addiction Psychiatry, American Board of Psychiatry and Neurology, Inc.
- 2004 Faculty, Research Colloquium for Junior Investigators, Annual Meeting, American Psychiatric Association, New York, New York, May 2
- 2005 – Member, Program Advisory Committee, Specialized Neuroscience Research Program (NINDS), Meharry Medical College, Nashville, Tennessee
- 2006 Faculty, Research Colloquium for Junior Investigators, Annual Meeting, American Psychiatric Association, Toronto, Ontario, Canada, May 21
- 2006 Member, Special Emphasis Panel/Scientific Review Group ZDA1 MXS-M (02) R, Novel Pharmacological Treatments for Drug Addiction, April 27-28
- 2006 Member, ZEY VSN (02) R, Training in Neuroimaging: Integrating First Principles and Applications, July 10
- 2007 Member, ZAA1 CC (13) R, Impact of Adolescent Drinking on the Developing Brain, July 18

- 2008 Member, ZRG1 IFCN-H 02 M, Member Conflicts: Addiction and Stress, February 20-21
- 2008 Member, ZRG1 IFCN-A 03, Member Conflicts: Neuropharmacology, July 14-15
- 2009 Member, ZDA1 EXL-T 06 1, Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders, February 9
- 2009 - Member, Federal Grant Advisory Panel, Renewal House, Nashville, Tennessee
- 2011 Member, ZDA1 SXC-E (12) R, Training in Neuroimaging (T90), March 31
- 2011 - Member, Diversity-Promoting Institutions Drug Abuse Research Program (DIDARP) External Advisory Committee, Meharry Medical College, Nashville, Tennessee
- 2013 - Projects Coordinator, International Network for the History of Neuropsychopharmacology (INHN)
- 2021 Reviewer, Pennsylvania Department of Health Formula Grants Final Performance Review 20-21 Cycle B

### **Editor-in-Chief**

Journal of Addictive Behaviors, Therapy & Rehabilitation, 2012 - 2016

### **Associate Editor**

Current Molecular Medicine, Anirban Maitra, M.D., Editor-in-Chief, 2000 - 2010

### **Editorial Board**

- 1994 – present Substance Abuse, Adam J. Gordon, M.D., M.P.H., Editor-in-Chief
- 2006 – present Science Advisory Board, SciMat (Science Matters in the Battle against Alcoholism and Related Diseases), a publication of the Betty Ford Center
- 2008 – 2011 Alcoholism: Clinical Experimental Research, Ivan Diamond, M.D., Ph.D., Editor-in-Chief
- 2008 – 2017 Drug, Healthcare and Patient Safety, Shufeng Zhou, M.D., Ph.D., Editor-in-Chief
- 2009 – present Neuropsychiatric Disease and Treatment, Roger M Pinder, Ph.D., D.Sc., Editor-in-Chief
- 2009 – 2017 Patient Related Outcome Measures, Robert Howland, M.D., Editor-in-Chief
- 2010 – present Journal of Addiction Research & Therapy
- 2010 – present Klinik Psikofarmakoloji Bulteni (Bulletin of Clinical Psychopharmacology), Mesut Cetin, M.D., Editor-in-Chief
- 2011 Editor, Special Issue on Neuroimaging of the Journal of Addiction Research & Therapy with David Newlin, Ph.D.
- 2011 – present DUSUNEN ADAM: The Journal of Psychiatry and Neurological Sciences, Editor-in-Chief, Cuneyt Evren, M.D.
- 2011 – 2015 Clinical and Experimental Pharmacology
- 2014 – present Journal of Reward Deficiency Syndrome, Kenneth Blum, Editor-in-Chief
- 2020 – present Cyprus Turkish Journal of Psychiatry and Psychology, Prof. Dr. Mehmet Çakıcı MD, PhD, Chief Editor

**Editorial Consultant**

Acta Neurologica Scandinavica  
Addiction

Alcohol Health and Research World  
Archives of General Psychiatry  
Biological Psychiatry  
Cochrane Dementia & Cognitive  
Improvement Group  
Depression and Anxiety  
Drug and Alcohol Dependence  
European Food Research and Technology  
Expert Review of Clinical Pharmacology  
Gene  
Goodman & Gilman's Ninth Edition of *The  
Pharmacological Basis of Therapeutics*  
Hospital Practice  
Journal of Affective Disorders  
Journal of Behavioral Addictions  
Journal of Magnetic Resonance Imaging  
Journal of Substance Abuse Treatment  
Lancet Psychiatry  
Nature Reviews Neurology  
Neuropsychopharmacology  
Pain Medicine  
PharmacoEconomics  
Physiology and Behavior  
Psychiatry Research  
Psychopharmacology Bulletin  
The American Journal of Clinical Nutrition  
  
The American Journal of Psychiatry  
Women's Health Issues

Acta Obstetrica et Gynecologica Scandinavica  
Alcoholism: Clinical and Experimental  
Research  
Annals of Neurology  
Behavioral and Brain Functions  
Clinical Pharmacology and Therapeutics  
Cognitive and Behavioral Neurology  
  
Diabetes Care  
European Journal of Neurology  
Expert Opinion on Pharmacotherapy  
Frontiers in Psychiatry  
General Hospital Psychiatry  
Journal of Addiction Medicine  
  
Journal of the American Geriatrics Society  
Journal of Clinical Psychopharmacology  
Journal of Neurochemistry  
Journal of the American Medical Association  
Magnetic Resonance Imaging  
NeuroImage  
New England Journal of Medicine  
Pediatrics  
  
Psychiatry Investigation  
Psychopharmacology  
Southern Medical Journal  
The American Journal of Obstetrics and  
Gynecology  
The American Journal on Addictions

### **Invited Lectures and Symposia (*since 2011*)**

Invited lectures prior to 2011 on various topics in Australia, Austria, Brazil, Canada, Colombia, Denmark, Finland, Guatemala, Hungary, Italy, Mexico, New Zealand, Puerto Rico, South Korea, and United Kingdom are not listed.

- 2011 "Coffee and Health", Coffee, Culture, and Community Development (Chaired by Edward Fischer), 100<sup>th</sup> Annual National Coffee Association Convention, New Orleans, Louisiana, March 17
- 2011 "Focus on Healing Addiction", 2<sup>nd</sup> Annual Lloyd C. Elam Symposium (Celebrating the 65<sup>th</sup> Anniversary of the Mental Health Association of Middle Tennessee and the Meharry Department of Psychiatry and Behavioral Sciences), Meharry Medical College, Nashville, Tennessee, March 25
- 2011 "Healing Addiction: Biopsychosocial Understanding as the Basis to Pharmacopsychosocial Treatment", Brookhaven Retreat, Seymour, Tennessee, May 27
- 2011 "Understanding and Healing Addiction: The "Cancer" of Behavior", Oncology Conference, San Francisco CA, October 13
- 2011 "Opioid dependence during pregnancy: balancing risk versus benefit" (Plenary Speaker) and "Neuroimaging in psychopharmacology: An update" (Chair), 4th International Congress on Psychopharmacology, Antalya, Turkey, November 24
- 2012 "Can coffee and cigarette consumption influence the course of alcohol dependence?" in Medical treatment of alcohol- and tobacco-dependence (Chaired by O.M. Lesch and K.O. Fagerstrom), Alcohol and Tobacco Interactions, ESBRA Nordmann Award and Congress of ESBRA, Basel, Switzerland, June 8
- 2012 "Understanding and healing addiction: prevention of the spread of HIV," Balance of care: from stigma to toxicity, 15<sup>th</sup> Annual HIV Symposium, Nashville TN, November 2
- 2012 "Can coffee and cigarette consumption influence the course of alcohol dependence?" at Universidad de los Andes, Bogota, Colombia, November 30
- 2016 "Opioid use during pregnancy: Magnitude of the problem and clinical pharmacologic strategies for management," in Bench to Bedside Symposium: The opioid addiction epidemic in the USA (Chaired by Sachin Patel), the Vanderbilt Program in Molecular Medicine, July 13
- 2016 "Transitioning from Methadone to Buprenorphine Maintenance in Management of Opioid Use Disorder during Pregnancy," Shakevia Johnson and Peter R. Martin, Oral Presentation, American Academy of Addiction Psychiatry, 27th Annual Meeting and Symposium, Bonita Springs, FL, December 11
- 2017 "Implications of the Co-occurrence of Substance Use and other Psychiatric Disorders," the Vanderbilt Program in Molecular Medicine, February 15
- 2019 "Approaches to Detoxification of patients during the Opioid Epidemic," Department of Psychiatry, UCLA Kern Medical Center, Bakersfield, CA, August 22
- 2020 "Opioid Use During Pregnancy: Strategies for Management," Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta GA, September 17
- 2020 "Scholarship of Everyday Life: Coffee," Robert Penn Warren Center for the Humanities and The Wond'ry, Vanderbilt University, Nashville TN, November 5

**ACADEMIC OR PROFESSIONAL HONORS:**

- McGill University Entrance Scholarship, 1971
- Listed in *Who's Who in Washington*, 1983
- U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental and Mental Health Administration, Special Achievement Award in Recognition of Contribution to The Fifth Special Report to the U.S. Congress on Alcohol and Health, 1985.
- Medal of the National Institute for Nervous and Mental Disorders (Hungary), 1989.
- Listed in *Who's Who in the South and Southwest*, since 23<sup>rd</sup> Edition, 1992.
- Listed in *Who's Who in Science and Engineering*, since 10<sup>th</sup> Edition, 2007.
- Listed in *Men of Achievement*, since 1992.
- Listed in *Who's Who of Emerging Leaders in America*, 4<sup>th</sup> Edition, 1992.
- Listed in *Who's Who in America*, since 53<sup>rd</sup> Edition, 1998.
- Listed in *Who's Who in Medicine and Healthcare*, since 1<sup>st</sup> Edition, 1996.
- Listed in *Who's Who in the World*, since 23<sup>rd</sup> Edition, 2005.
- Certificate of Recognition from the Tennessee Psychiatric Association and Tennessee Medical Foundation "For Meritorious Service and Singular Achievement in Service to Fellow Physicians Suffering from Addiction", November 3, 2001.
- Ambassador of Hope Award for Mental Health Program of the Year, The National Alliance for the Mentally Ill Nashville Inc., May 25, 2004.
- Listed in *Who's Who in the World*, since 2005
- Five Star Customer Service Award (for scoring in the top 10% nationally for "Excellent" responses, Medical Specialty Services Overall Quality of Doctor's Care), Professional Research Consultants, 2007
- Listed in *Guide to America's Top Physicians*, Consumers' Research Council of America, since 2007
- Honorary Professor of the International University, Vienna (for contributions through the Institute of Coffee Studies to strengthening international relations in the sphere of science, education, and business), Nomination Committee of Europe Business Assembly (Oxford, United Kingdom), 2008
- Top Performer Customer Service Award (our group, Addiction Psychiatry Clinic scored in the top 1% nationally for "Excellent" responses, Medical Specialty Services Overall Quality of Care), Professional Research Consultants, 2008
- Listed in *Guide to America's Top Psychiatrists*, Consumers' Research Council of America, since 2009
- Five Star Customer Service Award (our group, Addiction Psychiatry Clinic) scored in the top 10% nationally for "Excellent" responses, Medical Specialty Services Overall Quality of Care), Professional Research Consultants, 2009
- Certificate from the American Academy of Addiction Psychiatry "In recognition of your dedication and numerous contributions to the organization as Chair of the Annual Meeting Program Committee," December 4, 2009
- Top Performer Customer Service Award (our group, Addiction Psychiatry Clinic) scored in the top 1% nationally for "Excellent" responses, Medical Specialty Services Overall Quality of Care), Professional Research Consultants, 2010

Listed in *Leading Health Professionals of the World*, International Biographical Centre, Cambridge, England, since 2013

Outstanding Mentor Award from the American Academy of Child & Adolescent Psychiatry, "In Appreciation for Your Dedication and Devotion to the Success of the AACAP/NIDA K12 Physician Scientist Program in Substance Abuse (2010-2015)," presented at the AACAP 61<sup>st</sup> Annual Meeting, San Diego CA, October 2014.

Top 10 Doctor Nashville and Metro Area, Vitals, 2014.

Albert Nelson Marquis Lifetime Achievement Award, Listed in *Who's Who Lifetime Achievement*, 2018.

2018 Research Award, Department of Psychiatry and Behavioral Sciences, Vanderbilt University School of Medicine to mentee, Shakevia V. Johnson for the publication: "Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy" *The American Journal of Drug and Alcohol Abuse*, 2018, 44:3, 310-316.

### **TEACHING ACTIVITIES:**

- 1983 - 1986 Coordinator, Medical Student Elective, Laboratory of Clinical Studies, National Institute on Alcohol Abuse and Alcoholism
- 1986 - 2013 Coordinator for all teaching for the Department of Psychiatry in the subject area of addiction and substance-induced disorders. Medical student lectures given in Departments of Psychiatry (first, second and third years), Pharmacology (second year), and Medicine (second and fourth years). Lectures and supervision (all years) given to residents and during their rotations in the Division of Addiction Psychiatry. Lectures given at several Vanderbilt Continuing Medical Education events.
- 1987 - 1996 Member, Steering Committee, Vanderbilt Integrated Curriculum on Alcohol and Drugs
- 1990 - 1996 Chairman, Steering Committee, Vanderbilt Integrated Curriculum on Alcohol and Drugs
- 1993 - 2000 Member, Graduate Training Committee, Department of Psychiatry
- 1993 - 2000 Member, Resident Evaluation Committee, Department of Psychiatry
- 1996 - Preceptor, Premedical Summer Institute at Fisk and Vanderbilt Universities, Robert Wood Johnson Foundation
- 1997 - 2009 Director, Addiction Psychiatry Training Program (ACGME approved)
- 1999 - Preceptor, Introduction to Biomedical Research
- 2006 - 2011 Director, Addiction Psychiatry Interdisciplinary Research Training Program (NIDA-funded T-32 Award to train addiction psychiatrist physician-scientists)
- 2007 - 2012 Mentor, Emphasis Program, Vanderbilt University School of Medicine
- 2008, 10, 11 Faculty Uceptor, Vanderbilt Visions Program, a one-semester, university core program that encourages first-year undergraduates to be empowered and responsible members of the Vanderbilt University community
- 2012 - Facilitator, Case Based Learning in Curriculum 2.0, Vanderbilt University School of Medicine
- 2012 - Clinical Mentor, Howard Hughes Medical Institute/Vanderbilt University Medical Center Certificate Program in Molecular Medicine

- 2013 - Facilitator, Continuity Clinical Experience in Curriculum 2.0, Vanderbilt University School of Medicine
- 2014 - Supervision of Psychiatry Fellows, Residents and VUSM students on inpatient service of Vanderbilt Psychiatric Hospital and in Addiction Psychiatry Outpatient Clinic. Continue to give addiction lectures in VUSM and in Psychiatry Resident Curriculum.
- 2020 - 2021 Program Director, Addiction Psychiatry Training Program (ACGME approved)

### **RESEARCH PROGRAM:**

- Co-investigator, USPHS-NIAAA 1 R21 AA07388-01, "Psychotherapeutic Implications of an Alcohol Typology", Principal Investigator: Leslie Morey, Ph.D.; 12/01/87 to 12/31/89, direct costs - \$30,000.
- Co-investigator, USPHS-NIAAA 87-0018, "Develop, Implement and Evaluate An Integrated Model Program and Curriculum in Alcohol and Drug Abuse for Primary Care Physician Education", Principal Investigator: Anderson Spickard, M.D.; 08/01/87 to 06/30/89, annual direct costs - \$140,000.
- Principal Investigator, Boehringer Ingelheim Pharmaceuticals Inc., "Clonidine Treatment of Primary Alcohol Dependence", 07/01/89 to 06/30/90, direct costs - \$30,000.
- Co-Principal Investigator, Alcoholic Beverage Medical Research Foundation, "Molecular Genetics Analysis of the Role of Transketolase in Alcoholic Organic Brain Disease", Principal Investigator: Charles K. Singleton, Ph.D.; 01/01/90 to 12/31/90, direct costs - \$30,000.
- Principal Investigator, USPHS-NIAAA 1R01AA08492, "Genetic Mechanism(s) of Alcoholic Organic Brain Disease", 09/28/90 to 08/31/94, direct cost - \$479,067.
- Co-Principal Investigator, Alcoholic Beverage Medical Research Foundation, "Molecular Genetics Analysis of the Role of Transketolase in Alcoholic Organic Brain Disease", Principal Investigator: Charles K. Singleton, Ph.D.; 01/01/91 to 12/31/91, direct costs - \$10,000.
- Principal Investigator, USPHS-NIAAA 1TO1AA07515, "Faculty Development in Alcohol and Other Drug Abuse", 09/28/90 to 08/28/96, direct costs - \$434,204.
- Principal Investigator, American Medical Association Education and Research Foundation, "National Survey on Group Interventions with the Impaired Physician", 11/11/93 to 11/10/94, direct costs -\$7,851.
- Principal Investigator, USPHS-NIH 1R01 AA10433 "Molecular Mechanisms of Thiamine Utilization", 01/01/95 to 12/31/98, direct costs - \$481,044.
- Principal Investigator, USPHS-NIH 1R01 AA10583 "MR Spectroscopy Studies of Alcohol-Induced Brain Damage", 08/01/96 to 07/31/00, direct costs - \$749,129.
- Principal Investigator, U.S. Pharmaceutical Group, Pfizer Inc., "Double-Blind Parallel Comparison of Sertraline and Placebo in Patients with Depression and a DSM-IV Diagnosis of Alcohol Dependence", 09/01/96 to 06/01/99, total costs - \$275,000.
- Principal Investigator, U.S. Pharmaceutical Group, Pfizer Inc., "Double-Blind Continuation Study of Sertraline and Placebo in Subjects Who Have Completed Protocol No. R-0494 as Responders", 04/01/97 to present, total costs - \$64,375.
- Principal Investigator, Consortium of Coffee Producing Countries, "Institute for Coffee Studies", 07/01/99 to 06/30/02, total costs - \$3,380,995.

- Principal Investigator, American Foundation for Addiction Research, "fMRI Studies of Sexual Arousal in Normal Males", 09/01/00 to 06/30/00, total costs - \$60,000.
- Principal Investigator, American Foundation for Addiction Research, "fMRI Studies in Patients with Problematic Hypersexuality (Sexual Addiction)", 09/01/01 to 08/30/03, total cost - \$517,000.
- Principal Investigator, Drug Abuse Sciences, Inc., "Safety and Efficacy of Naltrel in Treatment of Alcohol Dependence", 05/01/01 to 06/30/02, total costs - \$128,000.
- Principal Investigator, Alkermes Inc., "A Phase III, Multi-Center, Randomized, Double Blind Placebo Controlled Study of the Efficacy and Safety of Medisorb Naltrexone in Alcohol Dependent Adults", 04/01/02 to 03/31/03, total costs - \$243,889.
- Principal Investigator, Alkermes Inc., "A Multi-Center, Double Blind, Extension of Alkermes Study ALK21-003 to Evaluate the Long Term Safety of Medisorb Naltrexone", 8/08/02 to 8/07/03, total cost - \$97,000.
- Principal Investigator, USPHS-NIH 1R01 DA015713 "Maternal Opioid Treatment: Human Experimental Research", 09/27/2004 - 06/30/2011, direct costs - \$1,960,467.
- Principal Investigator, USPHS-NIH 1R01 AA014969 "MR Studies of Alcohol-Induced Brain Injury and Recovery", 02/15/05 to 01/31/11, direct costs - \$1,354,346.
- Principal Investigator, USPHS-NIH 1T32 DA021123 "Linking Clinical Phenotypes and Molecular Underpinnings of Addiction", 04/01/2006 to 03/31/2011, direct costs - \$1,776,056.
- Principal Investigator, US WorldMeds/NIDA/VA Cooperative Studies Program, "A Phase III, Randomized, Multi-Center, Double Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification", 12/1/05 to 4/22/08, total cost - \$146,092.
- Principal Investigator, Catalyst Pharmaceutical Partners, Inc., "Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study", 07/01/2008 to present, total cost - \$224,322 (discontinued by manufacturer as corporate financial decision).
- Co-Investigator, USPHS-NIH 1R01AG034067-01 "Health Disparities and the Stress Hypothesis", Principal Investigator R. Jay Turner, Ph.D., 01/01/2010 to 08/31/2014, direct cost - \$2,684,453.
- Co-Investigator, USPHS-NIH-1R01HD074584-01 "Prescribed Opioid Safety in Children", Principal Investigator Wayne A. Ray, Ph.D., 1/1/2013 to 12/31/2017, annual direct cost - \$550,379.
- Co-Investigator, USPHS-NIH-1R03DA039743-01 "Characterizing non-medical prescription opioid use and pain in people living with HIV", Principal Investigator Aaron Kipp, Ph.D., 05/01/2015 - 03/31/2017, annual direct cost - \$200,000.
- Co-Investigator, USPHS-NIH-1R01DA045729-01 "Improving Access to Treatment for Women with Opioid Use Disorder", Principal Investigator Stephen Patrick, M.D., 4/1/2018 to 1/31/2022, total direct cost \$1,404,586.
- Senior Consultant, SAMHSA "Opioid Response Network: State Targeted Response-Technical Assistance Consortium", Principal Investigator Frances Levin, MD (Columbia University).
- Co-investigator, DHHS/OMH 1CPIMP171157-01-00 "Low versus high resource MAT equivalency study among persons with opioid use disorder", Principal Investigator Robert Cooper Ph.D. (Meharry Medical College).

- Co-Principal Investigator, USPHS-NIH-NIDA, 3UG1-DA040317-05S2: "CTN-0080: Medication treatment for Opioid use disorder in expectant Mothers (MOMs): a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations." Co-Principal Investigator Jessica Young, M.D.
- PI, TOBHP33102, Subaward 190618MK206: "Primary care training and enhancement (PCTE)". Principal Investigator Medhat Kalliny, M.D., Ph.D. (7/1/20-6/30/22).
- Co-investigator, USPHS-NIH-NIDA, "Applied epidemiology to arrest the HIV/HCV/opioid syndemic in the rural and urban South." Principal Investigator, Peter F. Rebeiro, Ph.D. (submitted).
- Co-investigator, USPHS-NIH-NIDA, "Advancing Treatment Outcomes for Pregnant Women with Opioid Use Disorder." Principal Investigator, Ashley Leech, Ph.D. (submitted).

### **RESEARCH TRAINEES:**

**Bryon Adinoff, M.D.**, Medical Staff Fellow, National Institute on Alcohol Abuse and Alcoholism (NIAAA), 1983-1986

*Training:* Supervised his studies of neuroendocrine functioning in alcoholism; trained in conduct and analysis of clinical research studies.

*At Retirement:* Distinguished Professor of Alcohol and Drug Abuse Research, Professor of Psychiatry, University of Texas Southwestern Medical School, Dallas TX

**Howard B. Moss, M.D.**, Medical Staff Fellow, NIAAA, 1983-1985

*Training:* Supervised his studies of pineal function in rats during alcohol intoxication and withdrawal; trained in conduct and analysis of clinical research studies.

*At Retirement:* Associate Director for Clinical and Translational Research, NIAAA, National Institutes of Health, Bethesda MD

**Giovanni Impeduglia, M.D.**, Visiting Fellow, NIAAA, 1983-1986

*Training:* Supervised his research on development of a rat model to study the pharmacogenetics of thiamine deficiency; trained in conduct and analysis of behavioral pharmacology and pharmacogenetic studies.

*Currently:* Private Practice in Pediatrics, Silver Springs MD

**George A.H. Bone, M.D.**, Medical Staff Fellow, NIAAA, 1984-1986

*Training:* Supervised his studies of hypertension in alcoholism and pharmacogenetics of alcohol metabolism; trained in conduct and analysis of clinical and laboratory studies.

*Currently:* Private Practice in Internal Medicine, Upper Marlboro MD

**David T. George, M.D.**, Medical Staff Fellow, NIAAA, 1985-1986

*Training:* Supervised his studies of anxiety and affective disorders in alcoholics and children of alcoholics; trained in conduct and analysis of biological psychiatry studies.

*Currently:* Senior Scientist, Office of the Clinical Director, Division of Intramural Clinical and Biological Research, NIAAA

**Sally J. Killian, M.D.**, Assistant Professor of Medicine (General Internal Medicine), Vanderbilt University School of Medicine, Faculty Fellow, NIAAA/NIDA funded Faculty Training Program in Alcohol and Other Drug Abuse, 1990-1991

*Training:* Conceptualization of alcoholism as a chronic disease in general internal medicine.

*Currently:* Private Practice in Internal Medicine, Nashville TN (deceased April 13, 2015)

**William B. Lawson, M.D., Ph.D.**, Assistant Professor of Psychiatry, Vanderbilt University School of Medicine, Faculty Fellow, NIAAA/NIDA funded Faculty Training Program in Alcohol and Other Drug Abuse, 1990-1991

*Training:* Treatment of psychoactive substance use disorders in patients with chronic mental illness.

*At Retirement:* Associate Dean for Health Disparities, Dell Medical School, University of Texas, Austin TX

**Ellen B. Hunter, M.D.**, Assistant Professor of Medicine (Gastroenterology), Vanderbilt University School of Medicine, Faculty Fellow, and NIAAA/NIDA funded Faculty Training Program in Alcohol and Other Drug Abuse, 1991-1993

*Training:* Assessment, treatment, and outcome of liver transplantation in patients with chronic alcoholism.

*Currently:* Private Practice in Internal Medicine (Gastroenterology and Hepatology), Boise ID

**Mark J. Werner, M.D.**, Assistant Professor of Pediatrics (Adolescent Medicine), Vanderbilt University School of Medicine, Faculty Fellow, and NIAAA/NIDA funded Faculty Training Program in Alcohol and Other Drug Abuse, 1990-1995

*Training:* Clinical screening for psychoactive substance use disorders in adolescents.

*Currently:* Director, Clinical Consulting, Physicians and Chartis Physician Leadership Institute, Chicago IL

**Amanda Nimmerrichter, M.D.**, Clinical Research Fellow, Vanderbilt University School of Medicine, 1991-1994

*Training:* Supervised her studies of genetic mechanisms of alcoholic organic brain disease; trained in conduct and analysis of clinical research studies using neuropsychology and neuroimaging techniques.

*Currently:* Private Practice in Psychiatry and Neurology, Vienna, Austria

**Terry L. Riutcel (Vital)**, Medical Student, Vanderbilt University School of Medicine, 1991-1995

*Training:* Studies of muscle metabolism in alcoholism using P-31 spectroscopy.

*Currently:* Department of Psychiatry, Barnes-Jewish Hospital, Saint Louis, Missouri

**Edward L. Hoffman, M.D.**, Assistant Professor of Pediatrics (Child Development), Vanderbilt University School of Medicine, Faculty Fellow, NIAAA/NIDA funded Faculty Training Program in Alcohol and Other Drug Abuse, 1991-1992

*Training:* Effects of intrauterine exposure to psychoactive substances on early human development.

*Currently:* Associate Professor of Clinical Practice, Pediatrics-Developmental Pediatrics, University of Colorado School of Medicine, Aurora, Colorado

**Theodora Phea, M.D.**, Assistant Professor of Pediatrics (Child Development), Vanderbilt University School of Medicine, Faculty Fellow, NIAAA/NIDA funded Faculty Training Program in Alcohol and Other Drug Abuse, 1992-1993

*Training:* Effects of intrauterine exposure to psychoactive substances on early human development.

*Currently:* Private Practice in Developmental Pediatrics, Nashville TN



**Evonne Charboneau, J.D., M.D.**, Trainee, Vanderbilt-Meharry Addiction Psychiatry Interdisciplinary Research Training Program, 2007-2009

*Training:* Neuroimaging of brain activation in response to food cues in obese children; effect of exercise on marijuana use disorder.

*Currently:* Assistant Research Professor, Division of Addiction Medicine, Department of Psychiatry, Vanderbilt University School of Medicine (deceased August 4, 2015)

**Michael Franklin, M.D.**, Trainee, Vanderbilt-Meharry Addiction Psychiatry Interdisciplinary Research Training Program, 2007-2009

*Training:* Neuroimaging studies of children at high risk for alcohol dependence.

*Currently:* Assistant Professor, Department of Psychiatry and Behavioral Science, Meharry Medical College, Nashville, Tennessee; Assistant Research Professor, Department of Psychiatry, Vanderbilt University School of Medicine

**Vidya Raj M.B., Ch.B.**, Resident in Psychiatry, Vanderbilt University School of Medicine, 2005-2006

*Training:* Oxcarbazepine in essential tremor.

*Currently:* Clinical Assistant Professor, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada

**Kelly E. Melvin M.D.**, Fellow, Child and Adolescent Psychiatry, Department of Psychiatry, Vanderbilt University School of Medicine, 2006-2008

*Training:* Treatment of posttraumatic stress disorder and alcohol dependence

*Currently:* Associate Professor, Department of Psychiatry and Behavioral Medicine, Marshall University School of Medicine, Huntington, West Virginia

**Margaret Benningfield, M.D.**, Trainee, Vanderbilt-Meharry Addiction Psychiatry Interdisciplinary Research Training Program, 2009-present

*Training:* Elucidating neurobiological mechanisms of risk for substance use disorders using fMRI approaches.

*Currently:* Assistant Professor and Director, Division of Child and Adolescent Psychiatry, Department of Psychiatry, Vanderbilt University School of Medicine

**Sachin Patel, M.D., Ph.D.**, Associate Professor, Departments of Psychiatry and Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 2011-2013

*Training:* Effects of exercise on the endocannabinoid system in human psychiatric diseases.

*Currently:* Chair, Lizzie Gilman Professor of Psychiatry and Behavioral Sciences and Psychiatrist-in-Chief of Northwestern Memorial Hospital Norman and Ida Stone Institute of Psychiatry, Northwestern University Feinberg School of Medicine, Evanston, Illinois

**Daniel F. Lonergan, M.D.**, Fellow, Division of Pain Medicine, Department of Anesthesiology, Vanderbilt University Medical Center, 2010-2011

*Training:* Characterization of the intrathecal opioid withdrawal syndrome.

*Currently:* Private Practice Pain Medicine, Crosby, Minnesota

**Jessica L. Young, M.D.**, Assistant Professor, Division of Fetal-Maternal Medicine, Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, 2011-present

*Training:* Management of opioid dependence in pregnancy.

*Currently:* Clinical Associate Professor, Division of Fetal-Maternal Medicine, Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine

**John Stephen Rich, M.D.**, Resident, Department of Psychiatry, Vanderbilt University School of Medicine, 2012-2015

*Training:* Co-occurring psychiatric disorder and alcoholism.

*Currently:* Private Practice Psychiatry, Nashville TN

**Aaron Kipp, Ph.D.**, Research Instructor, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, 2013 - present

*Training:* NIDA-funded, UCLA HIV/AIDS Substance Abuse and Trauma Training Program (HA-STTP)

*Currently:* Assistant Professor, Department of Public Health, East Carolina University Brody School of Medicine, Greenville, North Carolina

**Stephen W. Patrick, M.D., M.P.H., M.S.**, Assistant Professor, Department of Pediatrics, Vanderbilt University School of Medicine, 2014 – present

*Training:* Vanderbilt CTSA-funded Clinical and Translational Research Scholars Award (KL2)

*Currently:* Associate Professor, Department of Pediatrics, Vanderbilt University School of Medicine

**Shakevia V. Johnson, M.D., M.S.**, Resident, Department of Psychiatry and Behavioral Sciences, Vanderbilt University School of Medicine, 2014-2018

*Training:* Opioid use disorder during pregnancy.

*Currently:* Assistant Professor, Department of Psychiatry, Boston University School of Medicine, Boston MA

#### **Ph.D. Thesis Committees:**

**Marcia R. Smith, Ph.D.** (1989): Neuropsychological status, alcohol use patterns and personality as correlates of group process in alcohol abusers. (With L.C. Morey, Ph.D., Department of Psychology)

**Elizabeth S. Ochoa, Ph.D.** (1990): Client-therapist interactions: effects on retention in alcoholism treatment. (With L.C. Morey, Ph.D.)

**Brian A. McCool, Ph.D.** (1993): The role of human transketolase in Wernicke-Korsakoff syndrome: biochemical and molecular genetic investigations. (With C.K. Singleton, Ph.D., Department of Molecular Biology)

**James Wang, Ph.D.** (1996): Characterization of the assembly pathway and the catalytic behavior of human transketolase. (With C.K. Singleton, Ph.D.)

**Stevan R. Pekovich, Ph.D.** (1997): The biochemical and molecular responses to thiamine deficiency in human cells. (With C.K. Singleton, Ph.D.)

#### **PUBLICATIONS**

Google Scholar Citations 10,124; h-index=52; i10-index=125

\*Citation classics=27 (cited  $\geq$  100 times)

#### **Articles in refereed journals**

1. MacLeod SM, Sellers EM, Giles HG, Billings BJ, **Martin PR**, Greenblatt DJ, Marshman JA (1978): The interaction of disulfiram with benzodiazepines. *Clinical Pharmacology and Therapeutics* 24:583-589. [PMID: 29739](#)

2. **Martin PR**, Kapur BM, Whiteside EA, Sellers EM (1979): Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: A kinetic approach. *Clinical Pharmacology and Therapeutics* 26:256-264. [PMID: 455894](#)
3. **Martin PR**, Lefebvre A (1981): Surgical treatment of sleep apnea associated psychosis. *Canadian Medical Association Journal* 124:978-980. [PMID: 7260800](#)
4. **Martin PR**, Ebert MH, Gordon EK, Kopin IJ (1983): Urinary catecholamine metabolites and pharmacologic effects of clonidine in patients with alcohol amnestic disorder. *Clinical Pharmacology and Therapeutics* 33:19-27. [PMID: 6848295](#)
- \* 5. Weingartner H, Grafman J, Boutelle W, Kaye W, **Martin PR** (1983): Forms of memory failure. *Science* 221:380-382. [PMID: 6867715](#)
6. **Martin PR**, Ebert MH, Gordon EK, Kopin IJ (1983): Changes during clonidine treatment and clonidine withdrawal in urinary catecholamine metabolites in alcohol amnestic disorder. *Psychopharmacology Bulletin* 19:699-702.
7. **Martin PR**, Weingartner H, Gordon EK, Burns RS, Linnoila M., Kopin IJ, Ebert MH (1984): Central nervous system catecholamine metabolism in Korsakoff's psychosis. *Annals of Neurology* 15:184-187. [PMID: 6200058](#)
8. **Martin PR**, Ebert MH, Gordon EK, Weingartner H, Kopin IJ (1984): Catecholamine metabolism during clonidine withdrawal. *Psychopharmacology* 84:58-63. [PMID: 6436892](#)
9. **Martin PR**, Ebert MH, Gordon EK, Linnoila M, Kopin IJ (1984): The effects of clonidine on central and peripheral catecholamine metabolism. *Clinical Pharmacology and Therapeutics* 35:322-327. [PMID: 6199153](#)
10. **Martin PR**, Higa S, Burns RS, Tamarkin L, Ebert MH, Markey SP (1984): Decreased 6-hydroxymelatonin excretion in Korsakoff's psychosis. *Neurology* 34:966-968. [PMID: 6539875](#)
11. Eckardt MJ, Rawlings RR, Ryback RS, **Martin PR**, Gottschalk LA (1984): Effects of abstinence on the ability of clinical tests to identify male alcoholics. *American Journal of Clinical Pathology* 82:305-310. [PMID: 6465097](#)
12. **Martin PR**, Majchrowicz E, Tamborska E, Marietta C, Mukherjee AB, Eckardt MJ (1985): Response to ethanol reduced by past thiamine deficiency. *Science* 227:1365-1368. [PMID: 3975622](#)
13. **Martin PR**, Loewenstein RJ, Kaye WH, Ebert MH, Weingartner H, Gillin JC (1986): Sleep EEG in Korsakoff's psychosis and Alzheimer's disease. *Neurology* 36:411-414. [PMID: 3951711](#)
15. Adinoff B, Majchrowicz E, **Martin PR**, Linnoila M (1986): The benzodiazepine antagonist Ro 15-1788 does not antagonize the ethanol withdrawal syndrome. *Biological Psychiatry* 21:643-649. [PMID: 3011130](#)
16. Moss HB, Tamarkin L, Majchrowicz E, **Martin PR**, Linnoila M (1986): Pineal function during ethanol intoxication, dependence, and withdrawal. *Life Sciences* 39:2209-2214. [PMID: 3784775](#)
17. Impeduglia G, **Martin PR**, Kwest M, Hohlstein LA, Roehrich L, Majchrowicz E (1987): The influence of thiamine deficiency on the response to ethanol in two inbred rat strains. *Journal of Pharmacology and Experimental Therapeutics* 240:754-763. [PMID: 3559971](#)

- \* 18. Mukherjee AB, Svoronos S, Ghazanfari A, **Martin PR**, Fisher A, Roecklein B, Rodbard D, Staton R, Behar D, Berg CJ, Ramanathapuram M (1987): Transketolase abnormality in cultured fibroblasts from familial chronic alcoholic men and their male offspring. *Journal of Clinical Investigation* 79:1039-1043. [PMID: 3558815](#)
19. Linnoila M, Eckardt MJ, Durcan M, Lister R, **Martin PR** (1987): Interactions of serotonin with ethanol: clinical and animal studies. *Psychopharmacology Bulletin* 23:452-457.
20. Eckardt MJ, Rawlings RR, Graubard BI, Faden V, **Martin PR**, Gottschalk LA (1988): Neuropsychological performance and treatment outcome in male alcoholics. *Alcoholism: Clinical and Experimental Research* 12:88-93. (Republished in: *Annual Review of Addictions Research and Treatment*. Pergamon Press, New York, pp 309-314.) [PMID: 3279865](#)
21. Stapleton JM, Eckardt MJ, **Martin PR**, Adinoff B, Roehrich L, Bone G, Rubinow D, Linnoila M (1988): Treatment of alcoholic organic brain syndrome with the serotonin reuptake inhibitor fluvoxamine: A preliminary study. *Advances in Alcohol and Substance Abuse* 7:47-51. [PMID: 2464912](#)
22. Risher-Flowers D, Adinoff B, Ravitz B, Bone GHA, **Martin PR**, Nutt D, Linnoila M (1988): Circadian rhythms of cortisol during alcohol withdrawal. *Advances in Alcohol and Substance Abuse* 7:37-41. [PMID: 3223434](#)
23. Nutt DJ, Adinoff B, Ravitz B, George DT, Flowers D, Eckardt MJ, Bone GHA, **Martin PR**, Linnoila M (1988): Cerebro-spinal studies in alcoholics and violent offenders. *Australian Alcohol and Drug Review* 7:105-108.
24. **Martin PR**, Levin S, Impeduglia G, Karanian J, Mukherjee AB (1989): Thiamine deficiency *in utero* alters response to ethanol in adulthood. *Psychopharmacology* 97:253-256. [PMID: 2498935](#)
25. **Martin PR**, Impeduglia G, Rathna Giri P, Karanian J (1989): Acceleration of ethanol metabolism by past thiamine deficiency. *Alcoholism: Clinical and Experimental Research* 13:457-460. [PMID: 2665563](#)
26. **Martin PR**, Adinoff B, Eckardt MJ, Stapleton JM, Bone GHA, Rubinow DR, Lane EA, Linnoila M (1989): Effective pharmacotherapy of alcohol amnestic disorder with fluvoxamine: preliminary findings. *Archives of General Psychiatry* 46:617-621. [PMID: 2472126](#)
27. Bone GHA, Majchrowicz E, **Martin PR**, Linnoila M, Nutt DJ (1989): A comparison of calcium antagonists and diazepam in reducing ethanol withdrawal tremors. *Psychopharmacology* 99:386-388. [PMID: 2665563](#)
- \* 28. Adinoff B, **Martin PR**, Bone GHA, Eckardt MJ, Roehrich L, George DT, Moss H, Eskay R, Linnoila M, Gold PW (1990): Hypothalamic-pituitary-adrenal axis functioning and cerebrospinal fluid CRH and ACTH in alcoholics following recent and long-term abstinence. *Archives of General Psychiatry* 47:325-330. [PMID: 2157379](#)
29. Adinoff B, **Martin PR**, Eckardt MJ, Bone GHA, Gold PW, Linnoila M (1991): Pituitary-adrenal responses to oCRH and central neuropeptide levels in alcohol amnestic disorder. *Biological Psychiatry* 29:1153-1155. [PMID: 1651774](#)

- \*30. Adinoff B, Risher-Flowers D, DeJong J, Ravitz B, Bone GHA, Nutt DJ, Roehrich L, **Martin PR**, Linnoila M (1991): Disturbances of hypothalamic-pituitary-adrenal axis functioning during ethanol withdrawal in six men. *American Journal of Psychiatry* 148:1023-1025. [PMID: 1853950](#)
31. Adinoff B, Nemeroff CB, Bissette G, **Martin PR**, Linnoila M (1991): Inverse relationship between CSF TRH concentrations and the TSH response to TRH in abstinent alcohol-dependent patients. *American Journal of Psychiatry* 148:1586-1588. [PMID: 1656797](#)
32. **Martin PR**, Rio D, Adinoff B, Johnson JL, Bisserbe J-C, Rawlings RR, Rohrbaugh JW, Stapleton JM, Eckardt MJ (1992): Regional cerebral glucose utilization in chronic organic mental disorders associated with alcoholism. *Journal of Neuropsychiatry and Clinical Neuroscience* 4:159-167. [PMID: 1627977](#)
33. George DT, Lindquist T, Rawlings RR, Eckardt MJ, Moss H, Mathis C, **Martin PR**, Linnoila M (1992): Pharmacologic maintenance of abstinence in patients with alcoholism: No efficacy of 5-hydroxytryptophan or levodopa. *Clinical Pharmacology and Therapeutics* 52:553-560. [PMID: 1424429](#)
- \*34. McCool BA, Plonk SG, **Martin PR**, Singleton CK (1993): Cloning of human transketolase cDNAs and comparison of the nucleotide sequence of the coding region in Wernicke-Korsakoff and non-Wernicke-Korsakoff individuals. *Journal of Biological Chemistry* 268:1397-1404. [PMID: 8419340](#)
35. Joyce EM, Rio DE, Ruttimann UE, Rohrbaugh JW, **Martin PR**, Rawlings RR, Eckardt MJ (1994): Decreased cingulate and precuneate glucose utilization in alcoholic Korsakoff's syndrome. *Psychiatry Research* 54:225-239. [PMID: 7792327](#)
36. Gauvin DV, Briscoe RJ, Goulden KL, Wojnicki FH, Russin R, **Martin PR**, Holloway FA (1994): Influence of thiamine on the behavioral sensitivity to ethanol. *Alcoholism: Clinical and Experimental Research* 18:1398-1405. [PMID: 7695036](#)
37. Singleton CK, Pekovich SR, McCool BA, **Martin PR** (1995): The thiamine-dependent hysteretic behavior of human transketolase: Implications for thiamine deficiency. *Journal of Nutrition* 125:189-194. [PMID: 7861245](#)
38. **Martin PR**, Adinoff B, Lane E, Stapleton JM, Bone GAH, Weingartner H, Linnoila M, Eckardt MJ (1995): Fluvoxamine treatment of alcoholic amnestic disorder. *European Neuropsychopharmacology* 5:27-33. [PMID: 7542052](#)
- \*39. **Martin PR**, Gibbs JT, Nimmerrichter AA, Riddle WR, Welch LW, Wilcott MR (1995): Brain proton magnetic resonance spectroscopy studies in recently abstinent alcoholics. *Alcoholism: Clinical and Experimental Research* 19:1078-1082. [PMID: 7485820](#)
40. Lee H, Tarter J, Holburn G, Price RR, Weinstein DD, **Martin PR** (1995): *In vivo* localized proton NMR spectroscopy of thiamine-deficient rat brain. *Magnetic Resonance in Medicine* 34:313-318. [PMID: 7500868](#)
41. Eckardt MJ, Rohrbaugh JW, Stapleton JM, Davis EZ, **Martin PR**, Weingartner HJ (1996): Attention-related brain potential and cognition in alcoholism-associated organic brain disorders. *Biological Psychiatry* 39:143-146. [PMID: 8717614](#)
42. Welch LW, Nimmerrichter A, Kessler R, King D, Hoehn R, Margolin R, **Martin PR** (1996): Severe global amnesia presenting as Wernicke-Korsakoff syndrome but resulting from atypical lesions. *Psychological Medicine* 26: 421-425. [PMID: 8685298](#)

43. Pekovich SR, **Martin PR**, Singleton CK (1996): Thiamine pyrophosphate-requiring enzymes are altered during pyridoxamine-induced thiamine deficiency in cultured human lymphoblasts. *Journal of Nutrition* 126:1791-1798. [PMID: 8683340](#)
44. Roback HB, Moore RF, Waterhouse GJ, **Martin PR** (1996): Confidentiality dilemmas in group psychotherapy with substance-dependent physicians. *American Journal of Psychiatry* 153:1250-1260. [PMID: 8831431](#)
45. Adinoff B, Cantey Kiser JM, **Martin PR**, Linnoila M (1996): Response of dehydroepiandrosterone to corticotropin-releasing hormone stimulation in alcohol-dependent subjects. *Biological Psychiatry* 40:1305-1307. [PMID: 8959298](#)
46. Singleton CK, Wang JJ-L, Shan L, **Martin PR** (1996): Conserved residues are functionally distinct within transketolases of different species. *Biochemistry* 35:15865-15869. [PMID: 8961951](#)
47. Waterhouse GJ, Roback HB, Moore RF, **Martin PR** (1997): Perspectives of treatment efficacy with the substance dependent physician: a national survey. *Journal of Addictive Diseases* 16:123-138. [PMID: 9046448](#)
48. Welch LW, Cunningham AT, Eckardt MJ, **Martin PR** (1997): Fine motor speed deficits in alcoholic Korsakoff's syndrome. *Alcoholism: Clinical and Experimental Research* 21:134-139. [PMID: 9046386](#)
49. Wang JJ-L, **Martin PR**, Singleton CK (1997): A transketolase assembly defect in a Wernicke-Korsakoff patient. *Alcoholism: Clinical and Experimental Research* 21:576-580. [PMID: 9194907](#)
50. Welch LW, Nimmerrichter A, Gilliland, King DE, **Martin PR** (1997): "Wineglass" confabulations among brain-damaged alcoholics on the Wechsler Memory Scale-Revised Visual Reproduction subtest. *Cortex* 33:543-551. [PMID: 9339334](#)
51. Wang JJ-L, **Martin PR**, Singleton CK (1997): Aspartate 155 of human transketolase is essential for thiamine diphosphate-magnesium binding, and cofactor binding is required for dimer formation. *Biochimica Biophysica Acta* 1341:165-172. [PMID: 9357955](#)
52. Pekovich SR, **Martin PR**, Singleton CK (1998): Thiamine deficiency decreases steady-state transketolase and pyruvate dehydrogenase but not alpha-ketoglutarate dehydrogenase mRNA levels in three human cell types. *Journal of Nutrition* 128:683-687. [PMID: 9521628](#)
53. Pekovich SR, Poggi V, **Martin PR**, Singleton CK (1998): Sensitivity to thiamine deficiency in cultured human cells is dependent on cell type and is enhanced in cells from thiamine-responsive megaloblastic anemia patients. *Journal of Nutritional Biochemistry* 9:215-222.
54. Hartmann SL, Dawant BM, Parks MH, Schlack H, **Martin PR** (1999): Image-guided MR spectroscopy volume of interest localization for longitudinal studies. *Computerized Medical Imaging and Graphics* 22:453-462. [PMID: 10098893](#)
55. Onaivi ES, Chaudhuri G, Abaci AA, Parker M, Manier DH, **Martin PR**, Hubbard JR (1999): Expression of cannabinoid receptors and their gene transcripts in human blood cells. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 23:1063-1077. [PMID: 10621950](#)

56. Hartmann SL, Parks MH, **Martin PR**, Dawant BM (1999): Automatic 3-D segmentation of internal structures of the head in MR images using a combination of similarity and free-form transformations: Part II, validation on severely atrophied brains. *IEEE Transactions on Medical Imaging* **18**: 917-926. [PMID: 10628951](#)
57. Hartmann SL, Parks MH, Schlack H, Riddle W, Price RR, **Martin PR**, Dawant BM (1999): Automatic computation of brain and cerebellum volumes in normal subjects and chronic alcoholics. *Information Processing in Medical Imaging, Proceedings Lecture Notes in Computer Science* **1613**: 430-435.
- \* 58. de Paulis T, Schmidt DE, Bruchey AK, Kirby MT, McDonald MP, Commers P, Lovinger DM, **Martin PR** (2002): Dicinnamoylquinides in roasted coffee inhibit the human adenosine transporter. *European Journal of Pharmacology* **442**: 215-223. [PMID: 12065074](#)
- \* 59. Parks MH, Dawant BM, Riddle WR, Hartmann SL, Dietrich MS, Nickel MK, Price RR, **Martin PR** (2002): Longitudinal brain metabolic characterization of chronic alcoholics with proton magnetic resonance spectroscopy. *Alcoholism: Clinical and Experimental Research* **26**:1368-1380. (Abstracted in *Alcohol Research* **8**:19-20, 2003.) [PMID: 12351932](#)
60. Parks MH, Morgan VL, Pickens DR, Price RR, Dietrich MS, **Martin PR** (2003): Brain fMRI activation associated with self-paced finger tapping in chronic alcohol-dependent patients. *Alcoholism: Clinical and Experimental Research* **27**:704-711. (Reviewed in *Alcoholism: The Science Made Easy*. The Addiction Technology Transfer Center Network, Kansas City, Missouri, pp. 37-38.) [PMID: 12711934](#)
61. Kranzler H, Wesson DR., Billot L for the Drug Abuse Sciences Naltrexone Depot Study Group, including **Martin PR** and Weinstein DD at the Vanderbilt site (2004): Naltrexone depot for treatment of alcohol dependence: a multi-center, randomized, placebo-controlled clinical trial. *Alcoholism: Clinical and Experimental Research* **28**:1051-1059. [PMID: 16415699](#)
62. de Paulis T, Commers P, Farah A, Zhao J, McDonald MP, Galici R, **Martin PR** (2004): 4-Caffeoyl-1,5-quinide in roasted coffee inhibits [<sup>3</sup>H]naloxone binding and reverses antinociceptive effects of morphine in mice. *Psychopharmacology* **176**:146-153. [PMID: 15088081](#)
- \* 63. Farah A, de Paulis T, Trugo LC, **Martin PR** (2005): Effect of roasting on the formation of chlorogenic acid lactones in coffee. *Journal of Agricultural and Food Chemistry* **53**: 1505-1513. [PMID: 15740032](#)
- \* 64. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, **Martin PR**, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, Hasin D, Keller M. (2006): Sertraline treatment of co-occurring alcohol dependence and major depression. *Journal of Clinical Psychopharmacology* **26**:13-20. [PMID: 16415699](#)
- \* 65. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW for the Vivitrex Study Group, including **Martin PR** at the Vanderbilt site (2005): Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *Journal of the American Medical Association* **293**:1617-1625. [PMID: 15811981](#)

- \* 66. Farah A, de Paulis T, Moreira DP, Trugo LC, **Martin PR** (2006): Chlorogenic acids and lactones in regular and water-decaffeinated Arabica coffees. *Journal of Agricultural and Food Chemistry* 54:374-381. [PMID: 16417293](#)
- 67. Raj V, Landess JS, **Martin PR** (2006): Oxcarbazepine use in essential tremor. *The Annals of Pharmacotherapy* 40:1876-1879. [PMID: 16968828](#)
- 68. Melvin K, **Martin PR** (2008): Oxcarbazepine as a treatment for posttraumatic stress disorder and alcohol dependence: a case series. *The Journal of Pharmacy Technology* 24:149-53.
- \* 69. Perrone D, Farah A, Donangelo CM, de Paulis T, **Martin PR** (2008): Comprehensive analysis of major and minor chlorogenic acids and lactones in economically relevant Brazilian coffee cultivars. *Food Chemistry* 106:859-867.
- 70. Reich MS, Dietrich M, Finlayson R, Fischer E, **Martin PR** (2008): Coffee and cigarette consumption in recovering alcoholics participating in Alcoholics Anonymous in Nashville, TN. *Alcoholism: Clinical and Experimental Research* 32:1-8. (Reviewed in *Alcoholism: The Science Made Easy*. The Addiction Technology Transfer Center Network, Kansas City, Missouri.) [PMID: 18657129](#)
- \* 71. Jones HE, **Martin PR**, Heil SH, Stine SM, Kaltenbach K, Selby P, Coyle MG, O'Grady KE, Arria AM, Fischer G (2008): Treatment of opioid dependent pregnant women: clinical and research issues. *Journal of Substance Abuse Treatment* 35:245-259. [PMID: 18248941](#)
- 72. **Martin PR**, Arria AM, Fischer G, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Selby P, Jones HE (2009): Psychopharmacologic management of opioid dependent women during pregnancy *American Journal on Addictions* 18:148-156. [PMID: 19283567](#)
- 73. Jones HE, Heil SH, O'Grady KE, **Martin PR**, Kaltenbach K, Coyle MG, Stine SM, Selby P, Arria AM, Fischer G (2009): Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples. *American Journal of Drug and Alcohol Abuse* 35:375-380. [PMID: 20180667](#)
- 74. Stine SM, Heil SH, Kaltenbach K, **Martin PR**, Coyle MG, Fischer G, Arria AM, Selby P, Jones HE (2009): Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER Study. *American Journal of Drug and Alcohol Abuse* 35:429-433. [PMID: 20014912](#)
- 75. Unger A, **Martin PR**, Kaltenbach K, Stine SM, Heil SH, Jones HE, Arria AM, Coyle MG, Selby P, Fischer G (2010): Clinical characteristics of European and North American samples of pregnant women screened for opioid agonist treatment. *European Addiction Research* 16:99-107. [PMID: 20160444](#)
- 76. Parks MH, Dietrich MS, Greenberg DS, Nickel MK, Rogers BP, **Martin PR** (2010): Recruitment of additional brain regions to accomplish simple motor tasks in chronic alcohol-dependent patients. *Alcoholism: Clinical and Experimental Research* 34:1-12. [PMID: 20374203](#)
- 77. Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Fischer G, Jones HE, **Martin PR** (2010): Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. *American Journal on Addictions* 19:316-421. [PMID: 20716304](#)

- \*78. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, **Martin PR**, and Fischer G (2010): Neonatal Abstinence Syndrome following methadone or buprenorphine exposure. *New England Journal of Medicine* 363:2320-2331. (Reviewed in *Obstetrical & Gynecological Survey* 66:191-193, 2011.) [PMID: 21142534](#)
- \*79. Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, Stine S, Selby P, **Martin PR** (2011): Unintended pregnancy in opioid-abusing women. *Journal of Substance Abuse Treatment* 40:199-202. [PMID: 21036512](#)
- 80. Chisolm MS, Acquavita SP, Kaltenbach K, Winklbaur B, Heil SH, **Martin PR**, Stine SM, Coyle M, Leoutsakos JS, Tuten M, Jansson LM, Backer PM, Jones HE (2011): Cigarette smoking and neonatal outcomes in depressed and non-depressed opioid-dependent agonist-maintained pregnant patients. *Addictive Disorders & Their Treatment* 10:180-187. [PMID: 22833702](#)
- 81. Reich MS, Dietrich MS, **Martin PR** (2011): Temporal sequence of incident cigarette, coffee, and alcohol use among AA participants *The American Journal of Drug and Alcohol Abuse* 37:27-36. [PMID: 21128877](#)
- 82. Waddell KW, Zanjani P, Pradhan S, Xu L, Welch EB, Joers JM, **Martin PR**, Avison MJ, Gore JC (2011): Anterior Cingulate and Cerebellar GABA and Glu Correlations measured by <sup>1</sup>H J-Difference Spectroscopy. *Magnetic Resonance Imaging* 29:19-24. [PMID: 20884148](#)
- \*83. Buchowski MS, Meade NN, Charboneau E, Park S, Dietrich M, Cowan RL, **Martin PR** (2011): Aerobic exercise training reduces cannabis craving and use in non-treatment seeking cannabis-dependent adults. *PLoS ONE* 6(3): e17465. doi:10.1371/journal.pone.0017465. [PMID: 21408154](#)
- 84. Unger A, Jagsch R, Bäwert A, Winklbaur B, Rohrmeister K, **Martin PR**, Coyle M, Fischer G (2011): Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates? *Gender Medicine* 8:355-64. [PMID: 22088886](#)
- 85. Rogers BP, Parks MH, Nickel MK, Katwal S, **Martin PR** (2012): Reduced fronto-cerebellar functional connectivity in chronic alcoholic patients. *Alcoholism: Clinical and Experimental Research* 36:294-301. [PMID: 22085135](#)
- 86. Jackson TC, Lonergan DF, Todd RD, **Martin PR** (2013): Intentional intrathecal opioid detoxification in three patients: characterization of the intrathecal opioid withdrawal syndrome. *Pain Practice* 13(4):297-309. [PMID: 22925591](#)
- \*87. Jones HE, Heil SH, Bäwert A, Arria AM, Kaltenbach K, **Martin PR**, Coyle MG, Selby P, Stine SM, Fischer G (2012): Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. *Addiction* 107 Suppl 1:5-27. [PMID: 23106923](#)
- 88. Jones HE, Fischer G, Heil SH, Kaltenbach K, **Martin PR**, Coyle MG, Selby P, Stine SM, O'Grady Kevin E, Arria AM (2012): Maternal Opioid Treatment: Human Experimental Research (MOTHER)—approach, issues and lessons learned. *Addiction* 107 Suppl 1:28-35. [PMID: 23106924](#)
- 89. Holbrook A, Baxter J, Jones HE, Heil SH, Coyle MG, **Martin PR**, Stine SM, Kaltenbach K (2012): Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. *Addiction* 107 Suppl 1:83-90. [PMID: 23106930](#)

- \* 90. Kaltenbach K, Holbrook A, Coyle MG, Heil SH, Salisbury A, Stine S, **Martin PR**, Jones HE (2012): Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. *Addiction* 107 Suppl 1:45-52. [PMID: 23106926](#)
91. McNicholas L, Holbrook A, O'Grady K, Jones HE, Coyle MG, **Martin PR**, Heil SH, Stine SM, Kaltenbach K (2012). Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. *Addiction* 107 Suppl 1:91-7. [PMID: 23106931](#)
92. Benningfield MM, Dietrich MS, Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Fischer G, **Martin PR** (2012): Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. *Addiction* 107 Suppl 1:74-82. [PMID: 23106929](#)
93. Salisbury AL, Coyle MG, O'Grady KE, Heil SH, **Martin PR**, Stine SM, Kaltenbach K, Wenginger M, Jones HE (2012). Fetal assessment before and after dosing with buprenorphine or methadone. *Addiction* 107 Suppl 1:36-44. [PMID: 23106925](#)
94. Gaalema D, Linares Scott T, Heil SH, Coyle MG, Kaltenbach K, Badger GJ, Arria A, Stine SM, **Martin PR**, Jones HE (2012): Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. *Addiction* 107 Suppl 1:53-62. [PMID: 23106927](#)
95. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, **Martin PR** (2012): Nonserious adverse events in randomized trials with opioid-dependent pregnant women: direct versus indirect measurement. *American Journal on Addictions* 21: Suppl 1: S1–S4. [PMID: 23786504](#)
- \* 96. Epstein RA, Bobo WV, **Martin PR**, Morrow JA, Wang W, Chandrasekhar R, Cooper WO (2013): Increasing pregnancy-related use of opioid analgesics. *Annals of Epidemiology* 23:498-503. [PMID: 23889859](#)
97. Chisolm MS, Fitzsimons H, Leoutsakos JS, Acquavita SP, Heil SH, Wilson-Murphy M, Tuten M, Kaltenbach K, **Martin PR**, Winklbaaur B, Jansson LM, Jones HE (2013). A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. *Nicotine and Tobacco Research* 15(7): 1297-1304. [PMID: 23288871](#)
98. Holbrook A, Jones HE, Heil SH, **Martin PR**, Stine S, Fischer G, Coyle MG, Kaltenbach K (2013): Induction of pregnant women onto opioid-agonist maintenance medication: An analysis of withdrawal symptoms and study retention. *Drug and Alcohol Dependence* Pages 132:329–334. [PMID: 23523131](#)
99. Charboneau E, Dietrich MS, Park S, Cao A, Watkins TJ, Blackford JU, Benningfield M, **Martin PR**, Buchowski MS, Cowan RL (2013): Cannabis cue-induced brain activation correlates with drug craving in limbic and visual salience regions: preliminary results. *Psychiatry Research: Neuroimaging* 214:122–131. [PMID: 24035535](#)
100. Finlayson AJR, Neufeld R, Dietrich MS, Roback H, **Martin PR** (2013): Restoring professionalism: the physician fitness for duty evaluation. *General Hospital Psychiatry* 35(6):659-63. [PMID: 23910216](#)

101. Benningfield MM, Blackford JU, Ellsworth ME, Samanez-Larkin GR, **Martin PR**, Cowan RL, Zald DH (2014): Caudate responses to reward anticipation and delay discounting behavior in healthy youth. *Developmental Cognitive Neuroscience* 7:43-52. [PMID: 24309299](#)
102. Ferri M, Finlayson AJ Reid, Wang L, **Martin PR** (2014): Predictive factors for relapse in patients on buprenorphine maintenance. *American Journal on Addictions* 23(1):62-7. [PMID: 24313243](#)
103. Devin CJ, Lee DS, Armaghani SJ, Bible J, Shau DN, **Martin PR**, Ehrenfeld JM (2014): Approach to pain management in chronic opioid users undergoing orthopedic surgery. *Journal of the American Academy of Orthopedic Surgeons* 22:614-622. [PMID: 25281256](#)
104. Iannelli RJ, Finlayson AJR, Brown KP, Neufeld R, Gray R, Dietrich MS, **Martin PR** (2014): Suicidal behavior among physicians referred for fitness-for-duty evaluation. *General Hospital Psychiatry* 36:732-736. [PMID: 250857](#)
- \* 105. Patrick SW, Dudley J, **Martin PR**, Harrell FE, Warren MD, Hartmann KE, Ely EW, Grijalva CG, Cooper WO (2015): Prescription Opioid Epidemic and Infant Outcomes. *Pediatrics* 135:842-850. [PMID: 25869370](#)
106. Finlayson AJR, Brown KP, Iannelli RJ, Neufeld R, Shull K, Marganoff DP, **Martin PR** (2015): Professional sexual misconduct: the role of the polygraph in independent comprehensive evaluation. *Journal of Medical Regulation* 101:23-34.
107. de Paula Lima Juliana, Farah A, King B, de Paulis T, Martin PR (2016): Distribution of major chlorogenic acids and related compounds in Brazilian green and toasted *Ilex paraguariensis* (maté) leaves. *Journal of Agricultural and Food Chemistry* 64:2361-2370. [PMID: 26924157](#)
108. Gorodetzky C, Walsh S L, **Martin PR**, Saxon AJ, Gullo KL, Biswas K (2017): A phase III, randomized, multi-center, double-blind, placebo-controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. *Drug and Alcohol Dependence* 176:79-88. [PMID: 28527421](#)
109. Johnson SV, **Martin PR** (2018): Transitioning from methadone to buprenorphine maintenance in the management of opioid use disorder during pregnancy. *The American Journal of Drug and Alcohol Abuse* 44:310-316. [PMID: 28829626](#)
- \* 110. Kaltenbach K, O'Grady KE, Heil SH, Salisbury AL, Coyle MG, Fischer G, **Martin PR**, Stine S, Jones HE (2018): Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. *Drug and Alcohol Dependence* 185:40-49. [PMID: 29413437](#)
111. Patrick SW, Buntin MB, **Martin PR**, Scott TA, Dupont W, Richards M, Cooper WO (2018) Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian States. *Substance Abuse* 40:356-362. [PMID: 29949454](#)
112. Johnson KD, Miller LN, Pouliot JD, **Martin PR** (2019): Retrospective analysis of oxcarbazepine in pregnant women with substance use disorders: Focus on safety. *Journal of Pharmacy Practice* 34(1):28-34. [PMID: 31232158](#)

113. Patrick SW, Richards MR, Dupont WD, McNeer E, Buntin MB, **Martin PR**, Davis MM, Davis CS, Hartman KE, Leech AE, Lovell KS, Stein BD, Cooper WO (2020): Association of pregnancy and insurance status with treatment access for opioid use disorder. *JAMA Network Open*. 2020;3(8): e2013456. [PMID: 32797175](#)
114. Patrick SW, Slaughter JC, Harrell FE Jr., **Martin PR**, Hartmann K, Dudley J, Stratton S, Cooper WO (2020): Development and Validation of a Model to Predict Neonatal Abstinence Syndrome. *The Journal of Pediatrics* 229:154-160. [PMID: 33080277](#)
115. Phillippi J, Schulte R, Bonnet K, Schlundt DG, Cooper WO, **Martin PR**, Kozhimannil KB, Patrick SW (2021): Reproductive-Age Women's Experience of Accessing Treatment for Opioid Use Disorder: "We don't do that here". *Women's Health Issues* 31:455-461. [PMID: 34090780](#)
116. Finlayson AJR, Macoubrie J, Huff C, Foster DE, **Martin PR** (2022). Experiences with benzodiazepine use, tapering, and discontinuation: an internet survey. *Therapeutic Advances in Psychopharmacology* 11:1-10. [PMID: 35499041](#)
117. Cooper RL, Crosby RA, **Martin PR**, Edgerton R (2022): Averting neonatal abstinence syndrome and treating addiction among rural, opioid-using young women. *The American Journal on Addictions* 31(5):441-446. [PMID: 35535402](#)
118. Shrubsole MJ, Fan L, Zhu X, Yu C, **Martin PR**, Dai Q (2020): Nutrient Intake Adequacy and Diet Quality in Prescription Opioid Users in the National Health and Nutrition Examination Survey (NHANES) 2005-2016 *The Journal of Nutrition* (submitted).
119. Huff C, Finlayson AJR, Foster DE, **Martin PR** (2022). Enduring Neurological Sequelae of Benzodiazepine Use: An Internet Survey. *Therapeutic Advances in Psychopharmacology* (submitted).
120. Kropp FB, Smid MC, Lofwall MR, Wachman E, **Martin PR**, Murphy SM, Winhusen TJ (2022). Characterizing collaborative care programs for pregnant and post-partum individuals with Opioid Use Disorder: Organizational factors for sites participating in the NIDA CTN0080 MOMs study. *Journal of Substance Abuse Treatment* (submitted).

**Book chapters, invited review articles, etc.**

1. Sellers EM, **Martin PR**, Roy M, Sellers EA (1977): Alterations in temperature regulation associated with amphetamines. *Addiction Research Foundation Substudy No. 884*, Toronto.
2. Sellers EM, **Martin PR**, Roy M, Sellers EA (1979): Amphetamines. In *Body Temperature: Regulation, Drug Effects and Therapeutic Indications*. Lomax P, Schonbaum E (eds). Marcel Dekker, Inc., New York, pp. 461-498.
3. **Martin PR** (1979): Intravenous phenobarbital treatment of barbiturate and other hypnosedative withdrawal: A pharmacokinetic approach. Master of Science Thesis, Department of Pharmacology, University of Toronto.
4. **Martin PR**, Kapur BM, Whiteside EA, Janacek E, Sellers EM (1979): Intravenous phenobarbital treatment of barbiturate and other hypnosedative withdrawal reactions: A pharmacokinetic approach. *Addiction Research Foundation Substudy No. 1072*, Toronto.
5. **Martin PR** (1981): The human genetics of alcoholism. *Substance and Alcohol Actions/Misuse* 2:389-406.

6. Linnoila M, **Martin PR** (1983): Benzodiazepines and alcoholism. In, *Benzodiazepines Divided*. Trimble MR (ed). John Wiley and Sons, London, pp. 291-308.
7. **Martin PR**, Eckardt MJ (1985): Pharmacological interventions in chronic organic brain syndromes associated with alcoholism. In *Research Advances in New Psychopharmacological Treatments for Alcoholism*. Naranjo CA, Sellers EM (eds). Elsevier, Amsterdam, pp. 257-272.
- \* 8. Eckardt MJ, **Martin PR** (1986): Clinical assessment of cognition in alcoholism. *Alcoholism: Clinical and Experimental Research* 10:123-127. [PMID: 3521368](#)
- \* 9. **Martin PR**, Adinoff B, Weingartner H, Mukherjee AB, Eckardt MJ (1986): Alcoholic organic brain disease: nosology and pathophysiologic mechanisms. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 10:147-164. [PMID: 2875490](#)
10. Eckardt MJ, Rawlings RR, **Martin PR** (1986): Biological correlates and detection of alcohol abuse and alcoholism. *Progress in Neuro-Psychopharmacology Biological Psychiatry* 10:135-144. [PMID: 2875489](#)
11. Johnson JL, Adinoff B, Bisserbe JC, **Martin PR**, Rio D, Rohrbaugh JW, Zubovic E, Eckardt MJ (1986): Assessment of alcoholism-related organic brain syndromes with positron emission tomography. *Alcoholism: Clinical and Experimental Research* 10:237-240. [PMID: 3526943](#)
12. **Martin PR**, Mukherjee AB, Eckardt MJ (1986): Alcoholic organic brain disease. In *Biological Psychiatry 1985: Proceedings of the Fourth World Congress of Biological Psychiatry*. Shagass C et al (eds). Elsevier, Amsterdam, pp 1220-1222.
13. Eckardt MJ, **Martin PR** (1987): Diagnosis and treatment of chronic organic brain syndromes associated with alcoholism. *Substance Abuse* 8 (3):14-20.
14. Morey LC, **Martin PR** (1989): Assessment of alcoholism and substance abuse. In *Measuring Mental Illness. Psychometric Assessment for Clinicians*. Wetzler S (ed). American Psychiatric Press, Washington, DC, pp 161-181.
15. **Martin PR**, Eckardt MJ, Linnoila M (1989): Treatment of chronic organic mental disorders associated with alcoholism. In *Recent Developments in Alcoholism, Volume 7*. Galanter M (ed). Plenum, New York, pp 329-350. [PMID: 2648495](#)
16. Eckardt MJ, Rohrbaugh JW, Rio DE, **Martin PR** (1990): Positron emission tomography as a technique for studying the chronic effects of alcohol on the human brain. *Annals of Medicine (Finland)* 22:341-345. [PMID: 2291842](#)
17. Sunderland T, Molchan S, Martinez R, Vitiello B, **Martin PR** (1991): Drug challenge strategies in Alzheimer's disease: a focus on the scopolamine model. In *Alzheimer Disease: Current Research in Early Diagnosis*. Becker RE and Jacobini E(eds). Taylor & Francis, Publishers, New York, pp 173-191.
18. **Martin PR**, Kutcher M, Morey LC, Fjetland OK, Ban TA (1991): Depressive symptomatology associated with alcoholism using the CODE-DD. In *Functional Psychoses Today*. Aguglia E and Ban TA (eds). John Libbey, Rome, pp 305-314.
19. **Martin PR**, Charness ME (1993): Molecular mechanisms of brain damage in alcoholism. Introduction to the symposium. *Alcoholism: Clinical and Experimental Research* 17:1.
20. **Martin PR**, McCool BA, Singleton CK (1993): Genetic sensitivity to thiamine deficiency and development of alcoholic organic brain disease. *Alcoholism: Clinical and Experimental* 17:31-37. [PMID: 8452206](#)

21. **Martin PR**, Welch L (1993): Psychopharmacologic treatment of memory disorders. In *American Psychiatric Press Review of Psychiatry, Volume 12*. Oldman JM, Riba MB, Tasman A (eds). American Psychiatric Press, Washington, DC, pp 805-830.
22. **Martin PR**, Nimmerrichter A (1993): Pharmacologic treatment of alcohol-induced brain damage. In *Alcohol-Induced Brain Damage*. Hunt WA, Nixon SJ (eds). NIAAA Research Monographs, Washington, DC, pp 461-477.
23. Linnoila M, Fawcett J, Fuller RK, Harford TC, **Martin PR**, Meyer RE, Romach MK, Sellers EM (1994): Evaluation of pharmacologic treatments for alcohol abuse, dependence and their complications. In *Clinical Evaluation of Psychotropic Drugs: Principles and Guidance*. Prien RF and Robinson DS (eds). Raven Press, Ltd., New York, pp 625-649.
24. **Martin PR**, Lovinger DM, Breese GR (1995): Alcohol and other abused substances. In *Principles of Pharmacology: Basic Concepts and Clinical Applications*. Munson P, Mueller RA, Breese GR (eds). Chapman & Hall, New York, pp 417-452.
25. **Martin PR**, McCool, BA, Singleton CK (1995): Molecular genetics of transketolase in the pathogenesis of the Wernicke-Korsakoff syndrome. *Metabolic Brain Disease* 10:45-55. [PMID: 7596328](#)
26. Weinstein DD, **Martin PR** (1995): Psychiatric implications of alcoholism and traumatic brain injury. *American Journal on Addictions* 4:285-296.
27. **Martin PR**, Mathews GM (1995): Complications: cognition. In *Encyclopedia of Drugs and Alcohol*. Jaffe JH (ed). MacMillan Publishing Company, Inc., New York, NY, pp 263-265.
28. **Martin PR**, Pekovich SR, McCool, BA, Whetsell WO, Singleton, CK (1996): Thiamine utilization in the pathogenesis of alcohol-induced brain damage. In *The Biology of Alcohol Problems. Proceedings of the Seventh ISBRA Congress*. Saunders JB and Whitfield JB (eds). Elsevier Science Ltd., Tarrytown, NY. Published as Supplement No. 2 (1994) to the Journal *Alcohol and Alcoholism*, pp 273-279.
29. Hubbard JR, Martens J, **Martin PR** (1997): Alcohol and other substances of abuse. In *Primary Care Medicine for Psychiatrists: A Practitioner's Guide*. Hubbard JR, Short D (eds). Plenum Publishing Corporation, New York, NY, pp 211-230.
30. Franco SE, Hubbard JR, **Martin PR** (1997): Stress and addiction. In *Handbook of Stress Medicine: An Organ System Approach*. Hubbard JR, Workman EA (eds). CRC Press, Boca Raton, pp 187-203.
31. Ragan PW, Singleton CK, **Martin PR** (1999): Brain injury associated with chronic alcoholism. *CNS Spectrums* 4:66-87.
32. **Martin PR**, Hubbard JR (2000): Substance abuse related disorders. In *Current Diagnosis and Treatment in Psychiatry*. Ebert MH, Loosen PT, Nurcombe B (eds). McGraw-Hill Co., Inc., New York, NY, pp 233-259.
33. Ragan PW, **Martin PR** (2000): The psychobiology of sexual addiction. *Sexual Addiction and Compulsivity* 7:161-175.
- \* 34. Singleton CK, **Martin PR** (2001): Molecular mechanisms of thiamine utilization. *Current Molecular Medicine* 1:197-207.
35. Weinstein DD, **Martin PR** (2001): Neurological disorders and head injuries. In *Substance Abuse in the Mentally and Physically Disabled*, Hubbard JR and Martin PR (eds). Marcel Dekker, Inc., New York, NY, pp 277-305.

36. Hubbard JR, **Martin PR** (2001): Substance abuse in the mentally and physically disabled: an overview. In *Substance Abuse in the Mentally and Physically Disabled*. Hubbard JR and Martin PR (eds). Marcel Dekker, Inc., New York, NY, pp 1-10.
37. Lehmann LP, Hubbard JR, **Martin PR** (2001): Substance abuse and depression. In *Substance Abuse in the Mentally and Physically Disabled*. Hubbard JR and Martin PR (eds). Marcel Dekker, Inc., New York, NY, pp 33-58.
38. de Paulis T, **Martin PR**, Baker PS (2001): Health effects from coffee consumption. In *Coffee Futures: a source book of some critical issues confronting the coffee industry*. Feriva S.A., Cali, Colombia.
39. Finlayson R, Sealy J, **Martin PR** (2001): The differential diagnosis of problematic hypersexuality. *Sexual Addiction and Compulsivity* 8:241-251.
40. Skerl D, Pan S, Li R, Fitzpatrick JM, Parks MH, **Martin PR**, Morgan VL, Dawant BM (2001): Correction of geometric distortions in EP images using non-rigid registration to corresponding anatomic images. In *Proc. SPIE 4322, p. 58-68, Medical Imaging 2001: Image Processing*. Sonka M and Hanson KM (eds).
41. **Martin PR** (2002): Addiction psychiatry: rising from the ashes of molecular genetics, internal medicine, clinical pharmacology, and psychiatry. In *From Psychopharmacology to Neuropsychopharmacology in the 1980s and the Story of CINP, As Told in Autobiography*. Ban TA, Healy D, Shorter E (eds.). Animula Publishing House, Budapest, pp 95-100.
- \* 42. Sullivan EV, Harding AJ, Pentney R, Dlugos C, **Martin PR**, Parks MH, Desmond JE, Annabel Chen SH, Pryor MR, De Rosa E, Pfefferbaum A (2003): Disruption of frontocerebellar circuitry and function in alcoholism. *Alcoholism: Clinical and Experimental Research* 27:301-309. [PMID: 12605080](#)
- \* 43. **Martin PR**, Singleton CK, Hiller-Sturmhofel S (2003): The role of thiamine deficiency in alcoholic brain disease. *Alcohol Research and Health* 27(2):134-142. [PMID: 15740032](#)
44. de Paulis T, **Martin PR** (2004): Cerebral effects of noncaffeine constituents in roasted coffee. In *Coffee, Tea, Chocolate and the Brain*. Nehlig A (ed.). CRC Press, Boca Raton, pp. 187-195.
45. **Martin PR** (2004): Fundamental research, education, and dissemination of findings on coffee and health. In *New Research on coffee and health; proceedings of the International Seminar on Coffee and Health 40<sup>th</sup> Anniversary Meeting of the International Coffee Organization. Cartagena (Colombia), September 15, 2003*. Illy E and Pizano SD (ed.). The Commodities Press, Chinchina (Colombia), pp. 15-19. (Spanish translation available)
46. **Martin PR**, Petry NM (2005): Are non-substance-related addictions really addictions? *American Journal on Addictions* 14:1-7. (Most downloaded article from Volume 14.) [PMID: 15804872](#)
47. Heil S, Coyle MG, Fischer G, Jones HE, Kaltenbach K, **Martin PR**, Selby P, Stine SM (2006): The MOTHER (Maternal Opioid Treatment: Human Experimental Research) Study. *The Addictions Newsletter* 13:7-9. (Published by The American Psychological Association, Division 50)
48. **Martin PR**, Karila L (2007): Comprendre les troubles cérébraux induits par l'alcool à travers les études de neuroimagerie. *Alcoologie et Addictologie* 29:109-121.

49. **Martin PR** (2007): Understanding alcohol-induced brain disorders through neuroimaging studies. *Alcoologie et Addictologie* 29 (4 Suppl.) 2s-12s.
50. **Martin PR** (2008): Substance-related disorders. In *Current Diagnosis and Treatment: Psychiatry, Second Edition*. Ebert MH, Loosen PT, Nurcombe B, Leckman JF (eds). McGraw-Hill Co., Inc., New York, NY, pp. 230-260.
51. **Martin PR**, Patel S, Swift RM (2012): Pharmacology of drugs of abuse. In DA Golan, AH Tashjian, EJ Armstrong, AW Armstrong (eds.): *Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, Third Edition*. Lippincott Williams & Wilkins, Philadelphia, pp. 284-309.
52. Young JL, **Martin PR** (2012): Treatment of opioid dependence in the setting of pregnancy. *Psychiatric Clinics of North America* 35:441-60. [PMID: 22640765](#)
53. Rich SJ, **Martin PR** (2014): Co-occurring psychiatric disorders and alcoholism. In *Alcohol and the Nervous System. Handbook of Clinical Neurology, Volume 125 (3<sup>rd</sup> series)*. Sullivan EV and Pfefferbaum (eds.) Elsevier B.V., pp. 573-589. [PMID: 25307597](#)
54. **Martin PR**, Patel S (2017): Pharmacology of drugs of abuse. In DA Golan, EJ Armstrong, AW Armstrong (eds.): *Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, Fourth Edition*. Wolters Kluwer Health, Philadelphia, pp. 308-334.
55. **Martin PR** (2019): Substance-related and addictive disorders. In *Current Diagnosis and Treatment: Psychiatry, Third Edition*. Ebert MH, Leckman JF, Petrakis I (eds). McGraw-Hill Co., Inc., New York, NY, pp. 631-657.
56. Fischer EF, Victor B, Robinson D, Farah A, **Martin PR** (2019): Coffee consumption and health impacts: a brief history of changing concepts. In *Coffee Consumption and Health Implications*. Farah A (ed). The Royal Society of Chemistry, CPI Group (UK) Ltd, Croydon, United Kingdom, pp. 1-19.

### **Books**

1. *Substance Abuse in the Mentally and Physically Disabled*, Hubbard JR and **Martin PR** (eds). Marcel Dekker, Inc., New York, NY (2001). ISBN 978-0824-70587-9
2. *Healing Addiction: An Integrated Pharmacopsychosocial Approach to Treatment*, **Martin PR**, Weinberg BA, and Bealer BK. John Wiley and Sons, Hoboken, NJ (2007). ISBN 978-0471-65630-2
3. *Recollections of the History of Neuropsychopharmacology through Interviews Conducted by Leo E. Hollister*, **Martin PR**, Ban TA (eds). International Network for the History of Neuropsychopharmacology, Risskov, 2014 (<http://inhn.org>; Electronic book, February 6, 2014).
4. *Recollections of the History of Neuropsychopharmacology through Interviews Conducted by Thomas A. Ban*, **Martin PR** (ed). International Network for the History of Neuropsychopharmacology, Risskov, 2014 (<http://inhn.org>; Electronic book, July 24, 2014).

5. *Thomas A. Ban, Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener: INHN 2013*, **Martin PR** (ed). International Network for the History of Neuropsychopharmacology, Risskov, 2014 (<http://inhn.org>; Electronic book, December 25, 2014). Republished under same title in series on Educational E-Books, 2020.
6. *Thomas A. Ban Documenting the History of CINP*, **Martin PR** (ed). International Network for the History of Neuropsychopharmacology, Risskov, 2015. (<http://inhn.org>; Electronic book, January 1, 2015).
7. *Thomas A. Ban, Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener: INHN 2014*, **Martin PR** (ed). International Network for the History of Neuropsychopharmacology, Risskov, 2015 (<http://inhn.org>; Electronic book, December 31, 2015).
8. *Recollections of the History of Neuropsychopharmacology through Interviews Conducted by William E. Bunney, Jr.*, **Martin PR** (ed). International Network for the History of Neuropsychopharmacology, Risskov, 2016 (<http://inhn.org>; Electronic book, December 1, 2016).
9. *Recollections of the History of Neuropsychopharmacology through Interviews (Trilogy)*, **Martin PR** (ed). International Network for the History of Neuropsychopharmacology, Cordoba, Argentina. (<http://inhn.org>; Electronic book, December 23, 2019; December 30, 2019; January 6, 2019).
10. *Historical Vocabulary of Addiction*, **Martin PR**. (<http://inhn.org>; Electronic book, October 16, 2016—present).
11. *Thomas A. Ban, Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener: INHN 2013*, **Martin PR** (ed). INHN Publisher, Cordoba, Argentina (2020). ISBN 978-987-47722-2-0
12. *Thomas A. Ban, Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener: INHN 2014*, **Martin PR** (ed). INHN Publisher, Cordoba, Argentina (2022).
13. *Historical Vocabulary of Addiction*, **Martin PR**. INHN Publisher, Cordoba, Argentina (2022). ISBN: 978-987-47722-9-9
14. *Current Diagnosis and Treatment: Psychiatry, Fourth Edition*. Ebert MH, **Martin PR**, McVoy M, Ronis R, Weissman SH (eds). McGraw-Hill Co., Inc., New York, NY (2023).

### **Patents**

1. U.S. Patent No. 6,698,128: Substituted dicinnamoylquinides and their use in augmentation of adenosine function to de Paulis T, Lovinger DL, **Martin PR** (February 17, 2004). This invention describes the novel use of alkyl, alkoxy, halogenyl, or hydroxy substituted dicinnamoylquinides as therapeutic agents for enhancing adenosine levels in the brain and peripheral organs. These agents are particularly useful in treating human diseases or conditions that benefit from acute or chronic elevated levels of adenosine, such as reperfusion injury, coronary or cerebral ischemia, coronary vasoconstriction, paroxysmal supraventricular tachycardia, hypertension, wound healing, diabetes, inflammation, or sleep disturbances (and associated depression, anxiety, and alcohol dependence). They can also be used to protect normal cells from chemotoxicity in patients undergoing cancer therapy, and reverse the behavioral effects of caffeine intake.

***Letters to editor, book reviews, editorials, etc.***

1. **Martin PR** (1981): *Couple therapy*, F. Bockus (Book Review). *American Journal of Psychiatry* 138:712.
2. **Martin PR** (1983): *Dynamic approaches to the understanding and treatment of alcoholism*, Bean MH and Zinberg NE (eds) (Book Review). *American Journal of Psychiatry* 140:504.
3. **Martin PR**, Weingartner H, Gordon EK, Burns RS, Linnoila M, Kopin IJ, Ebert MH (1984): Reply to McEntee WJ, Mair RG: Catecholamines and amnesia: the need for psychometric verification. *Annals of Neurology* 16:516-517.
4. **Martin PR** (1986): *Cocaine*, Grinspoon L and Bakalar JB (Book Review). *The Psychiatric Times* 3(10)21.
5. **Martin PR**, Begtrup RO (1987): Straight talk ... about drugs. *Tennessee Teacher* 55(1):25-28.
6. **Martin PR** (1988): Alcoholic organic brain disease. *The Psychiatric Times* 5(4):16-18.
7. **Martin PR** (1990): *Assessment and treatment of addictive disorders*, Baker TB and Cannon DS (eds) (Book Review). *American Journal of Psychiatry* 147:116.
8. **Martin PR** (1990): *Theories on alcoholism*, Chaudron CD and Wilkinson DA (eds) (Book Review). *Journal of Clinical Psychiatry* 51:312.
9. **Martin PR**, Adinoff B, Eckardt MJ, Stapleton JM, Bone GAH, Lane EA, Linnoila M, Rubinow DR (1990): Reply to McEntee WJ, Mair RG: Memory improvement in Korsakoff's disease with fluvoxamine. *Archives of General Psychiatry* 47:978-979.
10. **Martin PR** (1991): *Huntington's Disease: a disorder of families*, Folstein SE (Book review). *American Journal of Psychiatry* 148:132-133.
11. **Martin PR** (1992): *Medical diagnosis and treatment of alcoholism*, Mendelson JH and Mello NK (eds) (Book Review). *New England Journal of Medicine* 328:1858-1859.
12. Adinoff B, **Martin PR**, Eckardt MJ, Linnoila M (1993): Role of DHEA and DHEA-S in Alzheimer's disease. *American Journal of Psychiatry* 150:1432-1433.
13. **Martin PR** (1993): *Memory function and aging-related disorders*, Morley JE, Coe RM, Strong R, Grossberg GT (eds) (Book Review). *American Journal of Psychiatry* 150:1744-1745.
14. **Martin PR** (1994): *Neurological aspects of substance abuse*, Brust JCM (Book Review). *New England Journal of Medicine* 330:724.
15. Hubbard JR, **Martin PR** (1997): *Relapse prevention by acamprosate: results from a placebo controlled study on alcohol dependence*, Sass H, Soyka M, Mann K, Zieglsangberger W (Article Review). *The Association of Medicine and Psychiatry* 6(2):3-7.
16. **Martin PR** (1997): How does alcoholism cause brain injury and who is most susceptible? *Kennedy Center News* 40(July/August): 1-4.
17. **Martin PR** (1997): Career profile: Addiction psychiatry combines basic sciences, internal medicine, clinical pharmacology, and general psychiatry. *Psychiatry Practice: A Resident's Perspective* 2(3):6-8.
18. Moore RF, Roback HB, Waterhouse GJ, **Martin PR** (1997): Confidentiality conundrum. *American Journal of Psychiatry* 154:1483-1484.

19. *Fact Sheet: Wernicke-Korsakoff Syndrome*. Prepared by the Family Caregiver Alliance in cooperation with California's Caregiver Resource Centers. Reviewed by **Peter R. Martin** (1998).
20. **Martin PR** (1999): *The integration of pharmacological and nonpharmacological treatments in drug/alcohol addictions*. Miller NS (ed) (Book Review). *Psychiatric Services* 50:277.
21. **Martin PR** (1999): *Clinical textbook of addictive disorders, 2<sup>nd</sup> edition*. Frances RJ, Miller SI (eds) (Book Review). *Journal of Clinical Psychiatry* 60:872.
22. **Martin PR** (2006): *Substance Abuse: A Comprehensive Textbook*. Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) (Book Review). *Journal of Clinical Psychiatry* 67:1475.
23. **Martin PR** (2006): *Cell Biology of Addiction*. Madras BK, Colvis CM, Pollock JD, Rutter JL, Shurtleff D, and von Zastrow M (eds) (Book Review). *New England Journal of Medicine* 354: 2301.
24. **Martin PR** (2006): *Neurobiology of Addiction*. Koob GF, Le Moal M (Book Review). *New England Journal of Medicine* 355:1743-1745.
25. **Martin PR** (2007): Substance addiction is no simple matter, *Tennessean* (06/07), Nashville TN (Editorial).
26. **Martin PR**, Daniel L (2011): Addiction: the big picture. *Journal of the Counsellors and Psychotherapists Association of NSW* 4:8-9.
27. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, **Martin PR**, Jansson L, Fischer G (2012): Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? (Letter to the Editor). *The Journal of Maternal-Fetal & Neonatal Medicine* 25:1197-1201. [PMID: 22292518](#)
28. Jones HE, Heil SH, Kaltenbach K, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, **Martin PR** (2012): Comments on: Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. *Journal of Addictive Diseases* 31(4):1-6. [PMID: 23244549](#)
29. **Martin PR**, Finlayson AJR (2012): Pharmacopsychosocial Treatment of Opioid Dependence: Harm Reduction, Palliation, or Simply Good Medical Practice? *Düşünen Adam the Journal of Psychiatry and Neurological Sciences* 2012(25):1-7.
30. **Martin PR** (2012): How do AAAP members translate scientific findings to clinical practice? *AAAP News* 28(3):9-10.
31. **Martin PR** (2013): Selective serotonin reuptake inhibitors and substance use disorders: a psychopharmacologic (mis)adventure? *AAAP News* 29(1):17-18.
32. **Martin PR** (2013): Management of opioid use disorder in pregnancy in the midst of the prescription opioid epidemic. *AAAP News* 29(2):17-18.
33. **Martin PR** (2013): Comments: The Q-T interval and the Mellaril story: a cautionary tale (Edward Shorter). <http://inhn.org>; Controversies. August 8.
34. **Martin PR** (2013): Comments: Addictions are not treatable diseases (Paul Devenyi). <http://inhn.org>; Controversies. September 12.
35. **Martin PR** (2013): Can obesity be understood as a *bona fide* addictive disorder? *AAAP News* 29(3):12-16.

36. **Martin PR** (2013): Comment to Reply: Addictions are not treatable diseases (Paul Devenyi). <http://inhn.org>; Controversies. October 31.
37. **Martin PR** (2014): Peter R. Martin's *Healing Addiction: An Integrated Pharmacopsychosocial Approach to Treatment*. <http://inhn.org>; Books. February 13.
38. **Martin PR** (2015): John R. Hubbard and Peter R. Martin's *Substance Abuse in the Mentally and Physically Disabled*. <http://inhn.org>; Books. January 15.
39. Finlayson AJR, **Martin PR** (2015): Benzodiazepines and suicide - time to wake up? *JAMA Psychiatry*. Published online December 17, 2014. doi:10.1001/jamapsychiatry.2014.1763; Posted on January 6, 2015; <http://archpsyc.jamanetwork.com/article.aspx?articleid=2019955>
40. **Martin PR**, Finlayson AJR (2015): Opioid Use Disorder during Pregnancy in Tennessee: Expediency vs. Science. *The American Journal of Drug and Alcohol Abuse* 41(5):367-370. PMID: 26186388
41. Gustin R, Nichols J, **Martin PR** (2015): Individualizing opioid use disorder (OUD) treatment: time to fully embrace a chronic disease model. *J Reward Deficiency Syndrome* 1(1):10-15; <http://blumsrewarddeficiencysyndrome.com/ets/articles/v1n1/jrds-003-richard-gustin.pdf>
42. **Martin PR** (2016): Understanding Drug and Alcohol Abuse and Addiction. <http://inhn.org>; Archives (Martin Collection). January 7.
43. **Martin PR** (2016): Alcoholism-Associated Brain Disorders: Psychiatric Nosology and Molecular Medicine. <http://inhn.org>; Archives (Martin Collection). January 21.
44. **Martin PR** (2016): Coffee and Health. <http://inhn.org>; Archives (Martin Collection). January 28.
45. **Martin PR** (2016): Treating Obesity as an Addiction (Can Obesity be Understood as a *Bona Fide* Mental Illness?). <http://inhn.org>; Archives (Martin Collection). February 11.
46. **Martin PR** (2016): Opioid Use Disorder During Pregnancy: Balancing Risk/Benefit <http://inhn.org>; Archives (Martin Collection). February 18.
47. **Martin PR** (2016): Substance Use Disorders Treatment: Pharmacopsychosocial Perspectives. <http://inhn.org>; Archives (Martin Collection). February 25.
48. **Martin PR** (2016): Understanding Alcohol Use disorder. <http://inhn.org>; Archives (Martin Collection). March 3.
49. **Martin PR** (2016): Opioid Dependence during Pregnancy: Balancing Risk/Benefit <http://inhn.org>; Archives (Martin Collection). March 10.
50. **Martin PR** (2016): Alcoholism, Hepatic Dysfunction, and Depression: How to Approach Management of this Patient? <http://inhn.org>; Archives (Martin Collection). June 2.
51. **Martin PR** (2016): Medical Complications of Alcoholism. <http://inhn.org>; Archives (Martin Collection). June 16.
52. **Martin PR** (2016): Historical Vocabulary of Addiction: Introduction. <http://inhn.org>; Ebooks. October 20.
53. **Martin PR** (2016): Historical Vocabulary of Addiction: Addiction. <http://inhn.org>; Ebooks. November 24.

54. **Martin PR** (2017): Detoxification of Patients from Central Nervous System Depressants: Which Protocol to Use and Why? <http://inhn.org>; Archives (Martin Collection). June 1.
55. **Martin PR** (2017): Implications of the co-occurrence of substance use and other psychiatric disorders <http://inhn.org>; Archives (Martin Collection). July 13.
56. Huff LC, **Martin PR**, Finlayson AJR (2017): Benzodiazepine Information Coalition Position Statement on the Use of Benzodiazepines in Patients Receiving Buprenorphine Treatment. <https://www.benzoinfo.com/single-post/2017/09/05/BIC-Position-Statement-on-the-Use-of-Benzodiazepines-in-Patients-Receiving-Buprenorphine-Treatment>. September 5, 2017.
57. **Martin PR** (2018): Historical Vocabulary of Addiction: Tolerance. <http://inhn.org>; Ebooks. February 1.
58. **Martin PR** (2019): Historical Vocabulary of Addiction: Withdrawal. <http://inhn.org>; Ebooks. May 30.
59. **Martin PR** (2019): Historical Vocabulary of Addiction: Alcoholism. <http://inhn.org>; Ebooks. June 26.
60. **Martin PR** (2019): Historical Vocabulary of Addiction: Opium. <http://inhn.org>; Ebooks. July 4.
61. **Martin PR** (2019): Peter R. Martin: Biographic Sketch. <http://inhn.org>; Biographies August 8.
62. **Martin PR** (2019): Historical Vocabulary of Addiction: Delirium Tremens. <http://inhn.org>; Ebooks. August 22.
63. **Martin PR** (2019): Historical Vocabulary of Addiction: Self-medication. <http://inhn.org>; Ebooks. November 14.
64. **Martin PR** (2019): Approaches to Detoxification of Patients during the Opioid Epidemic <http://inhn.org>; Archives (Martin Collection). December 19.
65. **Martin PR** (2019): Historical Vocabulary of Addiction: Conditioning. <http://inhn.org>; eBooks. December 26.
66. **Martin PR** (2020): Historical Vocabulary of Addiction: Self-help. <http://inhn.org>; Ebooks. January 2.
67. **Martin PR** (2020): Historical Vocabulary of Addiction: Recovery. <http://inhn.org>; Ebooks. February 20.
68. **Martin PR** (2020): Historical Vocabulary of Addiction: Blackout. <http://inhn.org>; Ebooks. May 7.
69. **Martin PR** (2020): Historical Vocabulary of Addiction: Intoxication. <http://inhn.org>; Ebooks. July 9.
70. **Martin PR** (2020): Historical Vocabulary of Addiction: Craving. <http://inhn.org>; Ebooks. August 27.
71. **Martin PR** (2020): Historical Vocabulary of Addiction: Motivation. <http://inhn.org>; Ebooks. September 10.
72. **Martin PR** (2020): Historical Vocabulary of Addiction: Resilience. <http://inhn.org>; Ebooks. October 1.
73. **Martin PR** (2020): Historical Vocabulary of Addiction: Sleep. <http://inhn.org>; Ebooks. November 5.

74. **Martin PR** (2020): Historical Vocabulary of Addiction: Pain. <http://inhn.org>; Ebooks. November 25.
75. **Martin PR** (2020): Historical Vocabulary of Addiction: Prevention. <http://inhn.org>; Ebooks. December 10.
76. **Martin PR** (2020): Historical Vocabulary of Addiction: Coffee. <http://inhn.org>; Ebooks. December 24.
77. **Martin PR** (2020): Historical Vocabulary of Addiction: Saliency. <http://inhn.org>; Ebooks. December 31.
78. **Martin PR** (2020): Historical Vocabulary of Addiction: Suicide. <http://inhn.org>; Ebooks. December 31.
79. **Martin PR** (2021): Historical Vocabulary of Addiction: Exercise. <http://inhn.org>; Ebooks. January 7.
80. **Martin PR** (2021): Historical Vocabulary of Addiction: Trauma. <http://inhn.org>; Ebooks. January 14.
81. **Martin PR** (2021): Historical Vocabulary of Addiction: Cannabis. <http://inhn.org>; Ebooks. January 28.
81. **Martin PR** (2021): Historical Vocabulary of Addiction: Nicotine. <http://inhn.org>; Ebooks. January 28.
82. **Martin PR** (2021): Historical Vocabulary of Addiction: Sedative. <http://inhn.org>; Ebooks. January 28.
83. **Martin PR** (2021): Historical Vocabulary of Addiction: Screening. <http://inhn.org>; Ebooks. February 11.
84. **Martin PR** (2021): Historical Vocabulary of Addiction: Gambling. <http://inhn.org>; Ebooks. February 18.
85. **Martin PR** (2021): Historical Vocabulary of Addiction: Stimulant. <http://inhn.org>; Ebooks. February 18.
86. **Martin PR** (2021): Peter Martin's Comments. Reid Finlayson's *Life on Lithium and Lessons Learned*. <http://inhn.org>; Ebooks. March 18.
87. **Martin PR** (2021): Historical Vocabulary of Addiction: Cocaine. <http://inhn.org>; Ebooks. March 25.
88. **Martin PR** (2021): Historical Vocabulary of Addiction: Aggression. <http://inhn.org>; Ebooks. April 22.
89. **Martin PR** (2021): Peter R. Martin's *Thomas A. Ban, Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener. International Network for the History of Neuropsychopharmacology: INHN 2013*. <http://inhn.org>; Books. April 28.
90. **Martin PR** (2021): Historical Vocabulary of Addiction: Wernicke-Korsakoff Syndrome. <http://inhn.org>; Ebooks. June 3.
91. *Wernicke-Korsakoff Syndrome*. Prepared by the National Organization for Rare Disorders. <https://rarediseases.org/rare-diseases/wernicke-korsakoff-syndrome/> Reviewed and Edited by **Peter R. Martin** (2021).
92. **Martin PR** (2021): Historical Vocabulary of Addiction: Acupuncture. <http://inhn.org>; Ebooks. June 17.
93. **Martin PR** (2021): Historical Vocabulary of Addiction: Addiction. Martin's Response to Charland's comment. <http://inhn.org>; Ebooks. June 24.

94. **Martin PR** (2021): Historical Vocabulary of Addiction: Kindling. <http://inhn.org>; Ebooks. July 8.
95. **Martin PR** (2021): Historical Vocabulary of Addiction: Empathy. <http://inhn.org>; Ebooks. September 2.
96. **Martin PR** (2021): Historical Vocabulary of Addiction: Wernicke-Korsakoff Syndrome. Martin's Response to Warnes' comment. <http://inhn.org>; Ebooks. October 7.
97. **Martin PR** (2021): Historical Vocabulary of Addiction: Mindfulness. <http://inhn.org>; Ebooks. October 14.
98. **Martin PR** (2021): Historical Vocabulary of Addiction: Opium. Martin's Response to Schioldann's comment. <http://inhn.org>; Ebooks. December 2.
99. **Martin PR** (2021): Historical Vocabulary of Addiction: Opium-Revised. <http://inhn.org>; Ebooks. December 9.
100. **Martin PR** (2021): Peter R. Martin's comments. Barry Blackwell's Introduction to Patrick Radden Keefe's Empire of Pain. <http://inhn.org>; Books. December 12, 2021.
101. **Martin PR** (2022): Historical Vocabulary of Addiction: Coffee. Martin's Response to Jose de Leon's comment. <http://inhn.org>; Ebooks. February 17.
102. **Martin PR** (2022): Eulogy for Thomas Arthur Ban (November 16, 1929 — February 4, 2022). <http://inhn.org>; Biographies. February 24.
103. **Martin PR** (2022): Historical Vocabulary of Addiction: Empathy. Martin's Response Hector Warnes' comment. <http://inhn.org>; eBooks. March 24.
104. **Martin PR** (2022): Historical Vocabulary of Addiction: Competence. <http://inhn.org>; Ebooks. April 20.
105. **Martin PR** (2022): Historical Vocabulary of Addiction: Wernicke-Korsakoff Syndrome. Peter Martin's response to Hector Warnes' reply to his comment. <http://inhn.org>; Ebooks. April 20.
106. **Martin PR** (2022): Historical Vocabulary of Addiction: Junkie. <http://inhn.org>; Ebooks. April 28.
107. **Martin PR** (2022): Peter R. Martin's comment. Edward Shorter: The Rise and Fall of the Age of Psychopharmacology <http://inhn.org>; Books. May 18.
108. **Martin PR** (2022): Historical Vocabulary of Addiction: Coffee. Martin's Response to Jose de Leon's comment. <http://inhn.org>; eBooks. May 19.
109. Finlayson AJR, Kim A, Mallory AB, Neufeld R, Vandekar S, **Martin PR** (2022): Changing characteristics of physicians referred for fitness-for-duty evaluation. *General Hospital Psychiatry* 77:128-129.
110. **Martin PR** (2022): Historical Vocabulary of Addiction: Sexual Addiction. <http://inhn.org>; eBooks. June 9.
111. **Martin PR** (2022): Award to Peter R. Martin for 35 years of service to Vanderbilt University Medical Center (June 27, 1986, to present) <http://inhn.org>; Archives (Martin Collection). August 4, 2022.
112. **Martin PR** (2022): Peter R. Martin's *Historical Vocabulary of Addiction*. <http://inhn.org>; Books. September 8.
113. **Martin PR** (2022): Historical Vocabulary of Addiction, Volume II: Breathalyzer. <http://inhn.org>; eBooks. September 15.

***Abstracts (published since 2014)***

134 abstracts published prior to 2012 are not listed.

Iannelli RJ, Finlayson AJR, Brown KP, Neufeld R, Gray R, Dietrich MS, **Martin PR** (2014): Suicidal behavior among physicians referred for fitness-for-duty evaluation. *Annual Meeting of the Federation of State Physician Health Programs*.

Kipp AM, Rogers WB, Bebawy S, Turner M, Sterling TR, Hulgan T, **Martin PR** (2016): Relationships between marijuana use and opioid pain reliever use and dosage in people living with HIV. *21<sup>st</sup> International AIDS Conference (AIDS 2016)*.

Kavur M, Kim A, **Martin PR** (2020): Nicotine dependence is associated with increased risk of addiction severity: a retrospective chart review. *Academic Psychiatry Day, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center*.

Finlayson AJR, Kim A, Vandekar S, **Martin PR** (2021): Unprofessional physician behavior. *Academic Psychiatry Day, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center*.

Updated: September 15, 2022